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ABSTRACT?
Cancer metastasis is a stepwise process of cancer cell dissemination from a primary tumour 
into adjacent and distant tissues and causes around 90 % of cancer-associated mortality. 
Metastatic cancer dissemination is initiated and promoted by intracellular and intercellular 
signalling within tumour microenvironment. Extracellular matrix (ECM) degradation also 
promotes cancer cell invasion and metastasis in many types of cancer. Membrane type-1 
matrix metalloproteinase (MT1-MMP) degrades variety of ECM components and cell surface 
proteins as well as modulates numerous intracellular signalling pathways to regulate cancer 
invasion. The molecular mechanisms of pro-invasive MT1-MMP activities are getting more 
attention to reveal cancer-associated cooperating signalling, which will aid in planning more 
efficient and effective therapeutic interventions for patients with cancer. 
In the current studies, we performed a genome-wide gain-of-function human kinome screen 
to identify cancer-associated upstream and co-operating signalling for MT1-MMP activities. 
We identified both known and novel positive regulators of MT1-MMP. Among the novel 
MT1-MMP regulators we focused on the functions of two receptor tyrosine kinases, namely 
fibroblast growth factor receptor 4 (FGFR4) and Eph receptor type A2 (EphA2) in cancer cell 
invasion. Overexpression and aberrant signalling of these kinases are linked to aggressive 
cancer progression and anti-cancer drug resistance.  
A single nucleotide polymorphism (SNP) of FGFR4 (G388R) associated with poor cancer 
prognosis was identified as a positive regulator of MT1-MMP activity. We revealed that the 
complexes of MT1-MMP and FGFR4-R388 risk variant stabilised and activated both MT1-
MMP and FGFR4 proteins, resulting in enhancing FGF signalling and pericellular proteolytic 
activities of MT1-MMP. The FGFR4-R388-MT1-MMP axis induced epithelial-to-
mesenchymal transition, promoting prostate carcinoma cell invasion and invasive growth 
within collagen matrix and in mouse xenograft models. In contrast, the FGFR4-G388 variant 
and MT1-MMP down-regulated each other.  
EphA2 was co-expressed with MT1-MMP in invasive breast carcinoma cells, where EphA2 
signalling increased MT1-MMP transcription. MT1-MMP in turn cleaved EphA2 in protein 
complexes on the same cell-surface. This cleavage coupled with EphA2-dependent Src 
activation triggered intracellular EphA2 translocation and an increase in RhoA activity, 
leading to actomyosine contraction, cell-cell repulsion, and cell junction disassembly. Theses 
signalling events ultimately induced cell invasion phenotype transition from collective to 
single-cell within three-dimensional collagen matrix and in vivo.  
Taken together, these studies identified the FGFR4-R388 variant and EphA2 as novel co-
operators for pro-invasive MT1-MMP activities in cancer invasion. FGFR4 genetic 
background affects the activity of an FGFR4-MT1-MMP complex in cancer progression, and 
an EphA2-MT1-MMP axis regulates cancer invasion plasticity. These findings provide novel 
insights into the cooperative molecular basis of pro-invasive capabilities of MT1-MMP and 
FGF and EphA2 signalling in cancer cell invasion.  
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REVIEW?OF?THE?LITERATURES?
INTRODUCTION?
Human cancer develops over decades through a multi-step process. A normal cell transforms 
into a neoplastic state by accumulating a number of genetic changes and acquiring new 
properties; e.g. uncontrolled cell growth, evasion of apoptosis, and activation of cancer cell 
invasion and metastasis. Cancer cells can thus disseminate from a primary tumour throughout 
the body and form new tumours in distant tissues and organs. At the initial step of metastatic 
cancer progression, the activated cellular signalling mediates cytoskeletal dynamics in cancer 
cells and dissociation of cell-cell and cell-matrix junctions in a primary tumour, promoting 
local cancer cell invasion into adjacent tissues. Cancer cells further invade into blood and 
lymph vessels. Circulating cancer cells then exit these capillaries by infiltrating the 
underlying basement membranes, enter a new microenvironement, and ultimately form 
metastatic colonies. These events are driven by orchestrated processes including cancer cell 
motility, extracellular matrix (ECM) remodelling, and cell-cell and cell-matrix 
communications. Furthermore, during metastatic tumour progression cancer cells can also 
switch their invasive machineries to adapt to their surrounding environment, which is 
implicated in aggressive cancer metastasis and resistance to anti-cancer treatment.   
In this work I have analysed the cooperative molecular mechanisms and cellular functions of 
pro-invasive MT1-MMP activities and FGF or Eph receptor tyrosine kinase signalling in 
cancer cells. I illustrate here the overview of cell-matrix and cell-cell communications within 
tumour microenvironment as well as cancer cell invasion plasticity. The review then focuses 
on human protein kinases. Specifically, I describe FGF and Eph receptor tyrosine kinase 
signalling in cancer. These signalling drive cancer progression or suppression in context-
dependent manner. Finally, I emphasize MT1-MMP functions in cancer cell invasion and 
metastasis. The findings in this thesis study provide the novel insights into the molecular 
mechanisms of the FGFR4- or EphA2-MT1-MMP axes in cancer progression and different 
modes of cancer cell invasion. Understanding the molecular mechanisms of cancer 
progression and cancer cell invasion plasticity is likely to help to develop effective anti-
invasion and anti-metastasis therapies. 
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1. Tumour?microenvironment??
Activation of cancer cell invasion and metastasis is one of the hallmarks of cancer that assists 
in transforming a locally growing primary tumour into a systemic and life-threatening disease 
(Friedl and Alexander, 2011; Hanahan and Weinberg, 2011). This is not a single-cell process, 
but rather involves orchestrated multifaceted processes that include cancer cell-cell and 
cancer cell-stroma interactions in tumour microenvironment. The stroma consists of 
extracellular matrix (ECM), stromal cells, and various soluble factors including growth 
factors,  chemokines,  cytokines,  and  antibodies.  Each  stromal  component  can  be  associated  
with tumour progression. 
1.1 Extracellular?matrix?(ECM)?
ECM provides structural support for multicellular architectures of tissues and organs (Hynes, 
2009; Lu et al., 2012). ECM affects also fundamental cell functions, e.g. cell proliferation, 
differentiation, polarity, and migration and invasion through physical cell-ECM interactions 
and by modulating intracellular signalling via cell-surface receptors (Hynes, 2009; Lu et al., 
2012). Structure and composition of ECM are constantly and dynamically remodelled, which 
is tightly controlled during developmental processes and in normal organ homeostasis. 
Impaired ECM dynamics is therefore implicated in many pathological conditions including 
cancer and tissue fibrosis (Lu et al., 2012). Aberrant ECM compromises its physical barrier 
and scaffolding functions, which can promote malignant transformation and progression 
through activation of oncogenic signalling pathways (Erler and Weaver, 2009; Lu et al., 
2012). Furthermore, abnormal ECM can also influence stromal cell behaviour in tumour 
microenvironment, and thus facilitate tumour-promoting angiogenesis and inflammation.  
1.1.1 Structure?of?ECM?
The ECM is a complex assembly of many proteins composed of fibrillar and non-fibrillar 
collagens, other fibrillar proteins (e.g. fibronectin, elastin, and laminin), as well as 
glycosaminoglycans (GAG) and GAG-containing proteoglycans (PG). These tissue 
compartments form elaborate meshwork structures that can be classified into two separate 
entities based on the morphological and functional properties: interstitial matrix and 
basement membrane (BM).  
1.1.1.1 Interstitial?matrix?
Interstitial matrix is a fibrillar three-dimensional (3D) meshwork structure (Egeblad et al., 
2010; Lu et al., 2012). The components of this type of matrix are mainly synthesized by 
fibroblasts (Kisseleva and Brenner, 2008; Lu et al., 2012). Interstitial tissue is rich in fibrillar 
collagens, glycoproteins, as well as various GAGs and PGs. This type of matrix is thus highly 
charged and hydrated, which contributes to elastic and tensile strength of tissues (Egeblad et 
al., 2010b; Lu et al., 2012).  
The main structural component of the interstitial ECM is type I collagen (Egeblad et al., 
2010; Myllyharju and Kivirikko, 2001). Cross-linked meshwork structure of ECM composed 
of three ?-chain polypeptides of type I collagen which is predominantly catalysed by stromal 
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fibroblast-derived lysyl oxidase (LOX). The collagen triple-helix structure provides tissues 
with stable mechanical strength and high resistance to proteolytic degradation (Egeblad et al., 
2010; Myllyharju and Kivirikko, 2001). Other major fibrillar proteins in this matrix are 
fibronectin and elastin (Hynes and Humphryes, 1974; Magnusson and Mosher, 1998; 
Ruoslahti and Vaheri, 1974). Fibronectin is a glycoprotein that is abundant in most of ECM 
(Magnusson and Mosher, 1998). Through the interaction with other ECM components and 
cell surface adhesion molecules, e.g. integrins via Arg-Gly-Asp (RGD) sequence, fibronectin 
regulates ECM organization and cell-ECM adhesion (Magnusson and Mosher, 1998; Mao 
and Schwarzbauer, 2005). Fibronectin also facilitates collagen fibril organization by binding 
collagen (Velling et al., 2002). Elastin forms stable cross-linked fibres associated with 
microfibrils that are composed of fibrillins and other proteins, such as latent transforming 
growth factor–??(TGF-?) binding proteins (LTBPs) (Hyytiainen et al., 2004). Elastic fibres 
form rubber-like polymers, which provide elastic stretch and recoil properties to special 
tissues such as blood vessels, lung, and skin (Kielty et al., 2002; Mithieux and Weiss, 2005).  
The meshwork structure composed of the fibrillar proteins is associated with various GAGs 
and GAG-containing PGs. GAGs are long unbranched polysaccharides containing a repeating 
disaccharide unit. The disaccharide units contain a sulphated sugar and an uronic acid such as 
glucuronate or iduronate. These sulphated GAGs attach covalently with core proteins and 
form PGs, such as aggrecan, decorin, and versican (Hardingham and Fosang, 1992; Kim et 
al., 2011). The only exception is hyaluronic acid which does not contain sulphate and does 
not bind proteins (Day and Sheehan, 2001). Hyaluronic acid is very hygroscopic, thus it is 
responsible for the gel-like character of tissues such as cartilage (Day and Sheehan, 2001). 
GAGs and PGs provide highly charged and aqueous environment surrounding cells, which 
allow rapid diffusion of small molecules such as salts, nutrients, and hormones (Hardingham 
and Fosang, 1992; Hynes, 2009; Kim et al., 2011). Importantly, PGs can act as reservoirs of 
growth factors, which may assist in the formation of gradients of the diffusible growth factor 
morphogens  as  well  as  accessibility  and  signalling  direction  of  ligands  to  their  cognate  
receptors (Hynes, 2009; Kim et al., 2011). For example, heparan sulphate proteoglycan 
(HSPG) acts as a co-factor for fibroblast growth factors (FGF) and its binding receptors 
(Hynes, 2009; Kim et al., 2011; Turner and Grose, 2010). Likewise, certain other growth 
factors such as a latent type TGF-?,  vascular  endothelial  growth  factor  (VEGF),  platelet  
derived growth factor (PDGF), and Wnt also bind to pericellular PGs during signalling 
transduction (Hynes, 2009; Kim et al., 2011).  
1.1.1.2 Basement?membrane?(BM)?
The BMs are specialized forms of thin dense sheet-like two-dimensional (2D) structures that 
are more compact and less porous than the interstitial matrix. The BMs underlie basolateral 
side to epithelial and endothelial cells, which supports apicobasal cellular polarity and tissue 
architecture (Kalluri, 2003). BMs also act as physical barriers, which separate the cells from 
stromal compartments (Kalluri, 2003). Unlike interstitial matrix, BMs consist mainly of 
network-forming type IV collagen, glycoprotein laminin, and linker proteins such as nidogen 
and perlecan (Kalluri, 2003; Rowe and Weiss, 2008). Laminin is a self-assembling protein, 
which is deposited to the basolateral side of the cell surface. The laminin network acts as a 
scaffold for further type IV collagen network formation and BM maturation (Kalluri, 2003). 
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Type IV collagen forms superstructures with highly cross-linked networks from six 
genetically different ?-chains (Kalluri, 2003). This laminin/ type IV collagen network is 
bridged by non-covalent interactions with linker glycoproteins, nidogens, and basement 
membrane-specific HSPG, perlecan. The whole network provides mechanical stability, 
selective filtration properties, and functions as a reservoir of growth factors for the BMs. 
Importantly, different isoforms of type IV collagen, laminin, and HSPG offer specific 
functions foe the BMs with different tissue types and organs (Kalluri, 2003; Rowe and Weiss, 
2008).   
1.1.2 ECM?Remodelling?in?Cancer?
In cellular microenvironment, the cells constantly modulate the structure and components of 
ECM by the activities of ECM remodelling enzymes, such as matrix metalloproteinases 
(MMP) and cross-linking enzyme, LOX (Barker et al., 2012; Cox and Erler, 2011; 
Kessenbrock et al., 2010; Lu et al., 2012). Reorganized ECM in turn influences adjacent cell 
functions and behaviour (Cox and Erler, 2011; Lu et al., 2012). Such cell-ECM bi-directional 
regulatory mechanism is tightly controlled, which maintains distinct tissue functions and 
organ homeostasis.  
In pathological conditions, the architecture of matrix is severely altered by aberrant ECM 
degradation, deposition, and structure modification (Cox and Erler, 2011; Lu et al., 2012). 
BMs are often thinner and porous in solid tumours (Rowe and Weiss, 2008). Perturbing 
scaffolding  and  physical  barrier  functions  of  BMs  can  affect  cell  polarity  and  growth,  and  
further promote cell invasion into adjacent interstitial matrix (Rowe and Weiss, 2008; Figure 
1A). Breaching the BMs is mainly performed by MMPs (Hotary et al., 2006; Ota et al., 
2009). For instance, membrane-anchored, membrane-type 1 (MT1-) MMP degrades the main 
components of BMs, such as type IV collagen and laminin (Giannelli et al., 1997; Hotary et 
al., 2006; Koshikawa et al., 2000; Ota et al., 2009). By cleaving BM components, MMPs 
generate biologically functional fragments, which can facilitate or inhibit cancer progression 
and invasion. For example, cleavage of laminin-5 by MT1-MMP and MMP2 generates pro-
migratory ?2 subunit fragments, while fragments generated from type XVIII collagen by 
MMPs play as tumour suppressors (Giannelli et al., 1997; Koshikawa et al., 2000; Lin et al., 
2001; Xu et al., 2001). 
Interstitial collagens including type I and III collagens are in turn frequently accumulated and 
highly cross-linked in solid tumours, which increase tissue thickness and stiffness (Egeblad et 
al., 2010; Kauppila et al., 1998; Lopez-Novoa and Nieto, 2009; Zhu et al., 1995). The 
thickened ECM increases the bioavailability of various soluble growth factors and cytokines 
to their cognate cell-surface receptors and thus promotes further cancer progression and 
cancer-associated inflammatory responses (Egeblad et al., 2010; Margadant and Sonnenberg, 
2010). The increased stiffness also enhances cell-ECM adhesion through mechano-
transduced signalling by increased integrin clustering and focal adhesion assembly, leading to 
efficient cancer cell invasion (DuFort et al., 2011; Levental et al., 2009). Concomitantly, 
collagen fibres are often linearized and oriented in parallel to the adjacent tumours or in 
perpendicular to stroma (Provenzano et al., 2006; Figure 1B). This architecture is associated 
with enhanced cancer cell invasion, since cancer cells can use the radially aligned collagen 
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fibres as migration tracks (Provenzano et al., 2006). Cancer cells also modify pre-metastatic 
location for subsequent colonization by secreting ECM remodelling enzymes and recruiting 
cancer-associated stromal cells (Erler et al., 2009).   
1.2 Communication?between?cancer?cells?and?stromal?cells??
During cancer progression, various types of stromal cells including fibroblasts, endothelial 
cells, and immune cells are recruited into a tumour. These cancer-associated stromal cells 
contribute to the tumour microenvironment formation together with cancer cells. 
Communication between cancer cells and these cells contributes to cancer progression 
(Hanahan and Coussens, 2012).  
1.2.1 Cancer-associated?fibroblasts?(CAF)?
Fibroblasts are the main producers of ECM components (Rasanen and Vaheri, 2010). During 
developmental processes, fibroblasts actively assist in tissue morphogenesis, while in adults 
they are usually quiescent (Rasanen and Vaheri, 2010). Under wound healing and 
pathological conditions including cancer, fibroblasts are induced to be in an “activated” state 
(Orimo and Weinberg, 2006; Rasanen and Vaheri, 2010). Pre-existing fibroblasts within 
tumour environment are converted into an activated state by autocrine TGF-? and stromal 
cell-derived factor-1 (SDF-1/ also known as CXCL12) signalling (Kojima et al., 2010). 
Alternatively, local mesenchymal stem cells (MSCs) and circulating bone marrow-derived 
MSCs are also recruited into a tumour by cancer cells (Direkze et al., 2004; Ishii et al., 2003). 
Such activated fibroblastic cells express ?-smooth muscle actin (?-SMC). They are widely 
called “cancer-associated fibroblasts” (CAF; Rasanen and Vaheri, 2010; Figure 1B).  
CAFs modulate components and structure of ECM within tumour microenvironment by 
expressing ECM components, growth factors, cytokines, and ECM remodelling enzymes (De 
Wever et al., 2008; Rasanen and Vaheri, 2010). By protease- and force-mediated matrix 
remodelling, CAFs degrade ECM and generate de novo gaps and microtracks that are used 
for cancer cell invasion by cohesive multicellular groups (Gaggioli et al., 2007; Scott et al., 
2010; Zhang et al., 2006). CAFs also express numerous growth factors and cytokines, such as 
SDF-1, TGF-?, and hepatocyte growth factor (HGF) and thus promote tumour growth and 
cancer cell invasion (Augsten et al., 2009; Bhowmick et al., 2004; De Wever et al., 2008; 
Orimo et al., 2005). Moreover, increased HGF and TGF-???in the pericellular milieu may 
further accelerate autocrine CAF generation (Tyan et al., 2011; Wipff et al., 2007). The direct 
contact of cancer cells with fibroblasts can promote unimpeded cancer cell migration in 
interstitial matrix through membrane-bound ephrin ligand and Eph receptor signalling (Astin 
et al., 2010). CAFs also mediate cancer-promoting angiogenesis and macrophage recruitment 
by producing or releasing pro-angiogenic soluble factors or inflammatory cytokines (Calvo 
and Sahai, 2011; Hanahan and Coussens, 2012; Orimo and Weinberg, 2006; Rasanen and 
Vaheri, 2010).  
1.2.2 Angiogenesis?and?lymphangiogenesis?
Along with increasing volume, a tumour requires nutrient, oxygen, and waste exchange 
(Hanahan and Weinberg, 2011). To supply these demands, tumours induce new sprouting of 
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endothelial cells from existing blood vessels, or recruit circulating bone marrow-derived 
endothelial progenitor cells (Bergers and Benjamin, 2003; Lyden et al., 2001; Purhonen et al., 
2008). At the initial step of angiogenesis, cancer cells, CAFs, and immune cells within 
tumour microenvironment produce and release pro-angiogenic growth factors (e.g. VEGFs, 
FGF2, and SDF-1) that recruit endothelial cell sprouting through paracrine signalling (Baluk 
et al., 2005; Bergers and Benjamin, 2003; Hanahan and Coussens, 2012; Weis and Cheresh, 
2011; Figure 1C). Sprouting endothelial tip cells require pericellular protease activities for 
degradation of endothelium BMs and interstitial matrix (Sounni et al., 2011; van Hinsbergh 
and Koolwijk, 2008). Besides ECM degradation, pericellular proteases are also involved in 
pro-angiogenic signalling activation (Sounni et al., 2011; van Hinsbergh and Koolwijk, 
2008).  For  example,  MT1-MMP  processes  LTBP  on  endothelial  cells  and  releases  pro-
angiogenic TGF-? (Tatti et al., 2008). This protease also generates biologically functional 
fragments by cleavage of thrombospondin-1 (TSP-1) and nidogen-1, which promotes 
neovascular development (Koziol et al., 2012). Unlike normal blood vessels, tumour-
associated vessels have poor basement membrane deposition and loose perivascular cell 
association with endothelial cells, resulting in porous and leaky blood vessels with abnormal 
blood flow (Baluk et al., 2005; Bergers and Benjamin, 2003). 
1.2.2.1 Cancer?cell?metastasis?through?circulation?
Fluid, proteins, and cells that leak out from the blood vessels are taken up by neighbouring 
lymphatic vessels via overlapping endothelial flaps (Norrmen et al., 2011). Lymphatic vessels 
are essential for transportation of immune cells (Tammela and Alitalo, 2010). Furthermore, 
together with blood vascular system, lymphatic capillaries are used as main routes for 
metastasizing cancer cell (Tammela and Alitalo, 2010; Weis and Cheresh, 2011; Figure 1D). 
Compared with blood vessels, lymphatic vessels have wider diameters as well as more porous 
and permeable walls (Norrmen et al., 2011; Tammela and Alitalo, 2010). These structural 
differences can influence metastatic cancer cell dissemination through blood or lymphatic 
vessels. For example, cohesive breast cancer cell groups enter only into lymphatic vessels, 
whereas singly invading cells after activation of TGF-? signalling can move into both blood 
and lymphatic capillaries, ultimately leading to blood-borne metastasis in vivo (Giampieri et 
al., 2009). Therefore, cancer cell metastasis into regional lymph nodes through lymphatic 
vessels is the first important step for cancer cell metastasis (Tammela and Alitalo, 2010). 
VEGF-C and VEGF-D produced by cancer cells and immune cells are the main pro-
lymphangiogenic factors that also promote cancer cell entry into lymphatic vessels and 
regional lymph nodes (Tammela and Alitalo, 2010).  
Direct contacts between cancer cells and endothelial cells through cell surface receptors 
regulate intra- and extravasation of cancer cells (Mierke, 2008). For extravasation of cancer 
cells from the circulation, circulating cancer cells interact with endothelium and underlying 
BMs and then degrade these barriers (Kargozaran et al., 2007; Reymond et al., 2012). 
Perivascular cancer-associated immune cells also assist in cancer cell intravasation (Wyckoff 
et al., 2007). Only a limited population of cancer cells achieves metastatic colonization due to 
the poor interaction of cancer cells and the endothelium in circulation and organ-specific 
barriers that block cancer cell extravasation (Nguyen et al., 2009).  
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1.2.3 Infiltrating?immune?cells?
Massive infiltration of immune cells including macrophages, neutrophils, T-cells and other 
leukocytes into tumours are frequently observed (Grivennikov et al., 2010; Mantovani et al., 
2008). The relationship of immune systems with cancer development is complex. In the early 
stage of tumour, immune cells inhibit tumour growth by recognition and rejection of cancer 
cells (Grivennikov et al., 2010; Mantovani et al., 2008). Cancer cells, in turn, can also 
manipulate certain immune cells to tumour promoting phenotypes by producing various 
cytokines and chemokines within tumour microenvironment (Hanahan and Weinberg, 2011; 
Joyce and Pollard, 2009; Mantovani et al., 2008). Cancer-associated leukocytes then obtain 
tumour-promoting functions whereby they can promote angiogenesis as well as cancer cell 
invasion, intravasation and ultimately metastasis (Hanahan and Coussens, 2012; Joyce and 
Pollard, 2009; Mantovani et al., 2008; Figure 1E). 
These cascades of communication between cancer cells and stromal cells will aid in 
generation of a tumour microenvironment that further facilitates cancer progression. 
 
Figure 1. Communications of cancer cells and stroma in tumour microenvironment. A) At the initial 
step of cancer invasion, cancer cells infiltrate into adjacent interstitial compartment by degrading 
BMs and interstitial matrix by ECM remodelling enzyme activities. B) Cancer cells also generate 
cancer-associated fibroblasts (CAFs), which contribute to abnormal ECM remodelling, e.g. ECM 
degradation and linearized interstitial collagen fibre formation. The linearized collagen fibres are 
oriented in perpendicular to stroma and used as a “highway” for invading cancer cells.  C) During 
tumour growth, cancer cells induce cancer-associated new blood and lymphatic vessel formation. 
D) Leaky tumour-associated vasculatures and lymphatic capillaries are used as routes for cancer 
cell dissemination to distant sites. E) In the late stage of tumour, immune cells are recruited to the 
tumour to promote cancer progression. (Adapted and modified from Lu et al., 2012). 
. 
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and direction (Friedl et al., 2001; Lammermann and Sixt, 2009; Wolf et al., 2003). Of note 
non-cancer cell migration is tightly controlled. Although cancer cells use similar mechanism 
for cell invasion as observed with non-cancer cells, they lost cell-cell contact-mediated 
immobilizing signalling and thus invade aggressively (Huttenlocher et al., 1998). 
2.1.1 Amoeboid-type?invasion?
Similar to amoeba and leukocyte migration, cancer 
cells display rounded sphere-like morphology in 
combination with low adhesion toward underlying 
matrix (Lammermann and Sixt, 2009). These cells 
invade at relatively high velocities (2-25 ?m/min) 
coupled with constant formation and retraction of 
blebs or other types of smooth membrane 
protrusions (e.g. pseudopodia) and change the cell 
shape ( Brabek et al., 2010; Lorentzen et al., 2011; 
Paluch et al., 2006; Poincloux et al., 2011). RhoA-
ROCK and Cdc42-Pak1-mediated actomyosin 
contractility drive this invasion mode, while activated Rac1 polarization at the leading edge is 
not required (Calvo et al., 2011; Friedl and Alexander, 2011; Sanz-Moreno and Marshall, 
2010; Figure 3). Amoeboid-type cells apt to invade in absence of integrin-mediated cell-ECM 
adhesion and MMP-dependent ECM remodelling (Wolf et al., 2003; Figure 3). The cells 
rather squeeze and intercalate between pre-existing gaps and trails within ECM matrix (Wolf 
et al., 2003).  
In addition to leukemias and lymphomas, amoeboid-type invading cells are also observed in 
subgroups of many types of carcinomas, such as breast, prostate, and small-cell lung 
carcinomas, as well as melanoma (Madsen and Sahai, 2010; Sanz-Moreno and Marshall, 
2010; Wolf et al., 2003).  
2.1.2 Mesenchymal-type?invasion?
Cancer cells can also invade as single-cells displaying elongated, spindle-shaped fibroblast-
like phenotype (Friedl and Alexander, 2011). The mesenchymal-type cell invasion is slower 
than amodboid-type invasion (0.1-2 ?m/min) driven by Rac1-mediated actin polymerization 
coupled with integrin-?1 and ?3-mediated cell-matrix adhesion as well as protease-dependent 
ECM remodelling (Friedl and Wolf, 2004; Sanz-Moreno and Marshall, 2010).  
The migration processes of mesenchymal-type invasion includes five separate steps as shown 
in Figure 4 (Friedl and Wolf, 2009; Friedl and Alexander, 2011). 1) Chemokine gradient or 
growth factor signalling initiate to polarize activated Rac1 and Cdc42 at the membrane 
ruffles, leading to actin stress fibre polymerization and formation of membrane protrusion 
(e.g. lamellipodia and filopodia) (Sanz-Moreno and Marshall, 2010). 2) The membrane 
protrusions adhere toward ECM through clustered integrins at focal adhesion sites that 
connect extracellular matrix to intracellular cytoskeleton. 3) MMPs degrade subcellular ECM 
followed by mechanical force to push connected ECM, generating a gap and migration track 
between matrixes. 4) An increased RhoA activation in central to rear part of migration cells 
Figure 3. Characters of an amoeboid-type 
single-cell invasion.  
(Adapted and modified from Friedl and 
Alexander, 2011 and Firedl et al., 2012) 
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collectively invading squamous carcinoma cells that retain epithelial characters (Chaudhry et 
al., 2013; Gaggioli et al., 2007). In addition, cells also invade in a manner dependent on 
placental (P)-cadherin-mediated cell-cell contacts, where cells in a group do not have specific 
leader cells and constitutively change their location (protrusive strand; Ewald et al., 2008; 
Gray et al., 2010; Nguyen-Ngoc et al., 2012; Figure 6D). The cells may rather use mechanical 
force to push surrounding ECM and to generate space for invasion (Ewald et al., 2008; Gray 
et al., 2010). To date, this type of collective invasion has been observed only during 
developmental processes including mammary branching (Ewald et al., 2008; Nguyen-Ngoc et 
al., 2012). However, the similar invasive mechanism would be predicted to be observed in 
pathological conditions.   
2.3 Plasticity?of?cancer?cell?invasion??
During metastatic cancer progression, invading cancer cells encounter different tissue 
microenvironment, consisting of a variety of ECM components, stromal cells, and soluble 
growth factors and cytokines. In addition, cancer therapy challenges, e.g. irradiation, 
chemotherapy, and surgery, can also contribute to microenvironment stress. To adapt to 
diverse microenvironmental conditions, cancer cells modulate their invasion modes by 
intracellular signalling through the cell surface receptors and cell-cell and cell-matrix 
interactions as well as by the physical properties of ECM (De Bock et al., 2011; Kargiotis et 
al., 2010; Friedl and Alexander, 2011; Wolf and Friedl, 2009). Cancer invasion is thus 
regarded as an adaptive and plastic process, which can facilitate cancer cell metastasis and 
further contribute to resistance to anticancer therapy (Alexander and Friedl, 2012). 
2.3.1 Collective-to-single?cell?transition?
 Collectively invading cancer cells can transit to 
individual phenotype in a tumour. For example, 
multicellular cohesive groups loose tight cell-cell 
contacts by down-regulation of cell-cell adhesion 
molecules, ultimately resulting in individual cell 
dissemination from multicellular groups 
(collective-to-single cell transition; Figure 7). 
Conversely, if singly moving cells up-regulate 
cell-cell adhesion molecules, the cells start to 
aggregate and move as cohesive multicellular groups (single-to-collective transition; Friedl 
and Alexander, 2011; Thiery et al., 2009; Figure 7). EMT and its reversible process 
mesenchymal-to-epithelial transition (MET) are involved in these processes.  
2.3.1.1 Epithelial-to-mesenchymal?transition?(EMT)?
During embryonic development and morphogenesis as well as in pathological conditions 
including cancer, epithelial cells can acquire mesenchymal capabilities, resulting in loss of 
tight contacts with their neighbours and apicobasal cellular polarity concomitant with gain of 
migratory and invasive capacities (Thiery et al., 2009). This is an important initial step for 
local cancer invasion. In addition to the motile property, cancer cells undergoing EMT gain 
Figure 7. Collective-to-single cell transition 
 (Adapted and modified from Friedl and 
Alexander, 2011 and Firedl et al., 2012) 
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anti-apoptotic and anti-senescence properties, and further stem cell-like characteristics 
(Thiery et al., 2009). 
In tumour microenvironment, many growth factors including FGF, HGF, EGF, TGF-?, and 
Wnt in stroma induce EMT of primary tumour cells, which can locally facilitate cell escape 
from a primary tumour into the adjacent ECM as multicellular groups or as single cells 
(Friedl et al., 2012; Polyak and Weinberg, 2009). In addition, hypoxic conditions, frequently 
existing in tumour microenvironment, also promote EMT by increasing the expression of c-
Met/HGF receptor in cancer cells that enhances HGF-induced cancer cell migration and 
dissemination (Pennacchietti et al., 2003). These signalling pathways activate one or several 
transcriptional repressors including ZEB1, Twist, and Snail 1 and 2, which inhibit E-cadherin 
transcription (Peinado et al., 2007; Vandewalle et al., 2009). Concomitantly, these E-cadherin 
repressors, e.g. Snails and Twist, can induce expression of mesenchymal phenotype-
associated cadherins, e.g. N-cadherin and cadherin-11, resulting in weakened cell-cell 
adhesion and disturbance of apicobasal cellular polarity (Peinado et al., 2007; Vandewalle et 
al., 2009). The downregulation or loss of E-cadherin coupled with up-regulation of N-
cadherin and/or cadherin-11 is known as “cadherin-switch”, which is one of the hallmarks of 
EMT to allow the cells to acquire motile mesenchymal-type spindle phenotype (Thiery et al., 
2009; Yilmaz and Christofori, 2010).   
The cells undergoing EMT can become tip cells located at the leading edge of cohesive 
multiple cell groups (Wolf et al., 2007). The cells further loosen cell-cell junctions; they can 
invade by multicellular streaming and/or mesenchymal-type individual cells. Furthermore, 
the cells acquire stem cell-like traits to disseminate to distant metastases as undifferentiated 
single cells (Polyak and Weinberg, 2009; Theveneau and Mayor, 2013; Thiery et al., 2009; 
Yilmaz and Christofori, 2010). Mesenchymal-type cells are characterized by cadherin-switch 
and upregulation of vimentin and MMPs including MMP1, MMP9, MT1-MMP and MT2-
MMP (Miyoshi et al., 2004; Tao et al., 2011; Vandewalle et al., 2009). These MMPs cleave 
E-cadherin and thus further facilitate cell-cell dissociation. Importantly, EMT is a reversible 
process that is transiently controlled in the local microenvironment. At the reached new 
microenvironment, the disseminated mesenchymal-type or stem cell-like undifferentiated 
cells from the primary tumours can revert to differentiated epithelial-like phenotype 
(mesenchymal-to-epithelial transition; MET) and ultimately form metastatic colonies, where 
EMT-inducible signalling are not activated (Polyak and Weinberg, 2009; Thiery et al., 2009; 
Yilmaz and Christofori, 2010).  
2.3.2 Mesenchymal-to-amoeboid?transition?
Singly invading cells can flexibly interchange 
between mesenchymal and rounded amoeboid-type 
phenotypes in different stages of metastatic process 
and therapeutic challenge (Alexander and Friedl, 
2012; Friedl and Alexander, 2011; Sanz-Moreno 
and Marshall, 2010; Figure 8). 
Figure 8.  Mesenchymal-to-amoeboid 
transition. 
(Adapted and modified from Friedl and 
Alexander, 2011) 
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4 Receptor?tyrosine?kinases?(RTKs)?in?cancer?
Receptor tyrosine kinases (RTK) are cell-surface receptors that have an intracellular tyrosine 
kinase domain. At cell surface, RTKs play critical roles in cell-cell and cell-ECM 
communications through binding to external signals and transmitting them into intracellular 
signalling cascades (Lemmon and Schlessinger, 2010). They regulate many of biological 
responses, such as cell proliferation, differentiation, survival, cell-cycle, intercellular 
communication and cell migration (Lemmon and Schlessinger, 2010). Human RTK is 
comprised of around 60 members that have been divided into 20 subfamilies. They share 
common structures with ligand-binding extracellular domain, a single-pass transmembrane 
domain, and cytoplasmic region that contain a protein kinase domain. Upon ligand binding, 
RTKs become catalytically active through phosphorylation of tyrosine residues and 
conformational changes within kinase domain. The activated RTKs then recruit signalling 
adaptor proteins to initiate multiple downstream signalling cascades (Lemmon and 
Schlessinger, 2010). The strength and retention of RTK signalling are regulated by ligand-
bound RTK internalization and endocytic trafficking (Parachoniak and Park, 2012). The 
internalized RTKs are transported into nucleus, recycling endosomes, or lysosomes or 
proteasomes where RTKs are degraded and thus RTK signal is terminated (Parachoniak and 
Park, 2012). 
Increased amount of evidence indicates that aberrant RTK signalling is implicated in cancer 
progression and cancer therapy resistance (Lemmon and Schlessinger, 2010; Parachoniak and 
Park, 2012; Witsch et al., 2010; Zhang et al., 2009). Indeed, many driver mutations have been 
found in different types of cancer (Lemmon and Schlessinger, 2010; Witsch et al., 2010). 
Deregulated and dysfunctional RTK signalling are frequently caused by gain-of-function 
mutation, SNP, RTK gene amplification, chromosomal translocation, and aberrant autocrine 
and paracrine signalling (Lemmon and Schlessinger, 2010; Witsch et al., 2010). 
4.1 Fibroblast?growth?factor?receptor?family??
The mammalian FGFR family comprises four 
members, FGFR1, FGFR2, FGFR3, and FGFR4, as 
well  as  one  additional  receptor,  FGFR5  (FGFRL1)  
(Turner and Grose,  2010).   FGFR5 does not contain a 
kinase domain but is  able to bind the ligands and may 
act as a negative regulator of FGFR signalling 
(Wiedemann and Trueb, 2000). FGFR1-4 have highly 
conserved structure. It consists of an extracellular 
region containing three immunoglobulin-like (Ig-like) 
domains, a single transmembrane domain (TM) and an 
intracellular TK domain (Turner and Grose, 2010; 
Figure 11). The second and third Ig-like domains can 
bind the ligands, FGFs that consist of 18 members 
(FGFs1-10, 16-23) (Turner and Grose, 2010). FGFs are 
secreted glycoproteins that are sequestered to ECM and 
cell surface by binding to HPSGs (Turner and Grose, 
 
Figure 11. Structure of FGFR. 
 Ig, immunoglobulin-like domain; 
TM, transmembrane domain; TK, 
tyrosine kinase domain  
(Adapted and modified from Turner 
and Grose 2010) 
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2010). HPSGs can also facilitate FGF-FGFR dimerization by simultaneously binding to both 
FGF and FGFR on the cell surface (Mohammadi et al., 2005; Turner and Grose, 2010). The 
specificity of FGF-FGFR interaction relies on alternative splicing variants of the receptors 
and tissue-specific expression pattern of FGF, FGFR, and HPSGs (Eswarakumar et al., 2005; 
Turner and Grose, 2010). Two splice variants in the Ig-III domain of FGFR1-3 provide b 
(FGFR1-3IIIb) and c (FGFR1-3IIIc) isoforms. The IIIb and IIIc isoforms are predominantly 
expressed in epithelial and mesenchymal cells respectively, and they display distinct FGF 
binding capacities (Beenken and Mohammadi, 2009). Each FGF binds to either epithelial or 
mesenchymal FGFRs, with the exception of FGF1 which activates both splice isoforms 
(Eswarakumar et al., 2005).  
4.1.1 FGF?signalling?
FGFRs have several tyrosine residues in their 
intracellular kinase domain. Ligand binding 
initiates FGFR dimerization and conformational 
shift in receptor structure that activates the 
intracellular kinase domain, further leading to 
cross-phosphorylation of tyrosine residues 
within  cytoplasmic  tail  (Turner  and  Grose,  
2010). Some of these phosphorylated residues 
act as docking sites for adaptor proteins 
containing Src homology 2 (SH2) domains, 
triggering multiple downstream signalling 
pathways including RAS-MAPK, PI3K-AKT, 
signal transducer and activator of transcription 
(STAT), phospholipase C? (PLC?) and Src 
(Turner and Grose, 2010; Figure 12). The main 
adaptor proteins, FGFR substrate 2? and ? 
(FRS2???) bind to the juxtamembrane region of 
FGFRs. The bound FRS2??? are phosphorylated 
by FGFRs and then associated with growth 
factor receptor-bound 2 (Grb2), leading to RAS-
MAPK signalling that regulates cell 
proliferation and differentiation, or AKT-dependent anti-apoptotic pathway. Recently it has 
been  reported  that  a  dimeric  Grb2  can  also  directly  bind  to  the  two FGFR2 molecules  and  
form a tetramer, which regulates FGFR2 activation in the presence and absence of 
extracellular stimuli (Lin et al., 2012). PLC? and Src bind to phosphotyrosine residues in the 
cytoplasmic tail of FGFRs. They trigger MAPK kinase signalling through PKC activation or 
Src signalling cascades coupled with Rho family GTPases that control cytoskeletal 
organization and migration (Eswarakumar et al., 2005; Turner and Grose, 2010). The FGFR 
downstream signalling activation is tightly controlled by a MAPK phosphatase-mediated 
negative feedback loop (Turner and Grose, 2010). Differences in downstream effector 
activation and biological functions are not dependent on specific FGF binding. This rather 
relies on cell type-specific adaptor protein expression and crosstalk with other signalling 
networks, such as Wnt signalling and HGF, PDGF or VEGF signalling (Dailey et al., 2005; 
Figure 12. FGFR signalling network.  
Upon ligand binding, the receptors are 
dimerized and phosphorylated at tyrosine 
residues (yellow). The activated FGFRs lead 
to five key downstream signalling cascades: 
RAS–RAF–MAPK, PI3K–AKT, STAT, PLC?, 
and Src (light blue). The signalling can be 
negatively regulated by modulating ligand 
binding (e.g. sef, orange) or by modulating 
intracellular MAPK signalling (e.g. Sprouty, 
orange).  
(Adapted and modified from Turner and 
Grose 2010) 
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Turner and Grose, 2010). Moreover, each FGFR has a different effect on downstream 
signalling activation. For example, the activation of downstream targets by FGFR4 is less 
strong than FGFR1 (Vainikka et al., 1994) and FGFR1 signalling lasts longer than FGFR2, 
since FGFR2 is degraded faster than FGFR1 after activation (Xian et al., 2007). 
4.1.2 FGF?signalling?in?cancer??
FGF signalling controls many fundamental cellular events in developmental processes 
including mesodermal patterning in embryo and subsequent formation of organs, such as 
skeletal development (e.g. limb and skull), the mammary and prostate gland formation as 
well as the nervous system generation (Eswarakumar et al., 2005; Ornitz and Marie, 2002; 
Turner and Grose, 2010). In adult, FGF signalling contributes to tissue homeostasis, wound 
healing, angiogenesis, and inflammation (Eswarakumar et al., 2005; Turner and Grose, 
2010). Thus, deregulation of this signalling activation can lead to developmental disorders 
and cancer, as explained below (Beenken and Mohammadi, 2009; Turner and Grose, 2010; 
Wesche et al., 2011).  
4.1.2.1 Gain-of-function?mutations??
Several FGFR mutations that confer constitutive kinase activation have been found in a 
number of congenital skeletal dysplasia. The most common genetic form of dwarfism in 
human, Achondroplasia, is caused by a point mutation in the transmembrane domain of 
FGFR3 (FGFR3-G380R). The conformational changes in the FGFR3-R380 mutant induce 
aberrant kinase activation through constitutive dimer formation and receptor stabilization 
(Cho et al., 2004; Eswarakumar et al., 2005). Moreover, point mutations in the similar 
transmembrane location and in extracellular Ig-III domain of FGFR1 and FGFR2, as well as 
another mutation in transmembrane domain, FGFR3-A391E, cause craniosynostosis that are 
characterized with premature fusion of skull sutures and cranial deformities (Eswarakumar et 
al., 2005; Meyers et al., 1995; Pulleyn et al., 1996; White et al., 2005).  
These  gain-of-function  mutations  of  FGFRs have  also  been  found in  many types  of  cancer  
(Wesche et al., 2011). Glioblastoma exhibit multiple mutations in FGFR1 kinase domain 
(Rand et al., 2005), while FGFR2 mutants have been found in 12 % of endometrial cancer 
(Dutt et al., 2008) and more rarely in gastric cancer (Jang et al., 2001). In addition, various 
FGFR3 mutations are widely detected in many types of cancer, including bladder (50–60 % 
non-muscle invasive type, 10–15 % invasive type), myeloma (5 %), and prostate cancer (3 %; 
Turner and Grose, 2010; Wesche et al., 2011). Unlike FGFR1-3, none of FGFR4 mutations 
have been reported to be implicated to developmental disorders. However, several mutants 
are associated with progression of certain cancer. FGFR4-N535K and V550E mutations in 
FGFR4 tyrosine kinase domain were found in childhood soft tissue sarcoma, 
rhabdomyosarcoma (Taylor JG et al., 2009). More recently, a constitutive active mutant, 
FGFR4-Y367C in extracellular domain was identified in MDA-MB-453 breast carcinoma 
cells (Roidl et al., 2010). Overexpression of this mutant allows malignant cells to escape from 
doxorubicin treatment as well as promotes aberrant cell proliferation and tumour growth 
through MAPK/ERK signalling activation (Roidl et al., 2009; Roidl et al., 2010).  
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4.1.2.2 Single?nucleotide?polymorphism?(SNP)?
Germline SNPs have been identified in FGFRs that are associated with some types of cancer 
predisposition. Several SNPs in FGFR2 have been found to be highly associated with breast 
cancer risk (Tenhagen et al., 2012). The risk variants of FGFR2 increase the affinity to runt-
related transcription factor (RUNX), resulting in increased expression of FGFR2 that 
associates with breast cancer development (Meyer et al., 2008; Tenhagen et al., 2012). 
One SNP in the transmembrane domain of FGFR4 that leads to change of glycine to an 
arginine at amino acid position 388 (FGFR4-G388R) has been linked to poor prognosis of 
patients with several types of tumours such as breast, prostate, colon, lung, head and neck 
squamous cell carcinoma, high-grade soft tissue sarcoma, as well as melanomas (Bange et al., 
2002; da Costa Andrade et al., 2007; Sasaki et al., 2008; Spinola et al., 2005; Streit et al., 
2004; Wang et al., 2004). In contrast, in some other carcinomas including malignant gliomas 
and advanced ovarian cancer, this SNP is not associated with cancer progression (Marme et 
al., 2012; Mawrin et al., 2006). In some cases, the expression of FGFR4-R388 variant in 
these carcinomas is even related to prolonged survival and a better prognosis (Marme et al., 
2012; Mawrin et al., 2006). The study using WAP-TGF? transgenic mouse carrying FGFR4-
G385R mutation (analogous to the human G388R) shows it to accelerate mammary 
carcinoma growth and lung metastasis (Seitzer et al., 2010). This was associated with 
increased transformation and migration/invasion of FGFR4-G385R mouse embryonic 
fibroblasts (Seitzer et al., 2010). The FGFR4-R388 risk variant also promotes human prostate 
carcinoma cell migration through stabilization and elongation of FGF signalling compared to 
the alternative FGFR4-G388 low risk variant (Wang et al., 2008). In contrast to the high risk 
variant, the FGFR4-G388 variant expression is associated with a better prognosis of prostate 
and breast carcinomas (Bange et al., 2002; Stadler et al., 2006). The risk variant in breast 
carcinomas can be a possible marker for adjuvant systemic chemotherapy resistance 
(Thussbas et al., 2006). On the other hand, the FGFR4-R388 variant can be associated with 
better clinical and pathological response under neoadjuvant chemotherapy treatment (Marme 
et al., 2010).   
4.1.2.3 Chromosomal?translocations?
FGFR1 and FGFR3 chromosomal translocations have been identified in hematologic 
malignancies, resulting in a fusion protein comprising N-terminus of a transcriptional factor 
fused to the C-terminus of FGFR kinase domain. The fusion protein is constitutively 
dimerized in the absence of ligand, resulting in activation of FGFR kinase activity (Turner 
and Grose, 2010). Most of FGFR1 fusion proteins were identified in patients with the 
myeloproliferative disorder stem cell leukaemia/lymphoma syndrome, while multiple 
myelomas bear FGFR3 translocation  that  is  associated  with  worse  prognosis  of  patients  
(Avet-Loiseau et al., 1998; Kalff and Spencer, 2012; Turner and Grose, 2010). This 
translocation leads to FGFR3 overexpression through a strong IgH promoter activity (Kalff 
and Spencer, 2012).  
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4.1.2.4 Gene?amplification?and?overexpression?
FGFR gene  amplification  often  leads  to  FGFR  overexpression,  which  can  promote  ligand-
independent signalling (Wesche et al., 2011). Amplification of FGFR1 occurs in 
approximately 10% of estrogen receptor (ER)-positive breast carcinomas, which is linked to 
aggressive cancer progression and shorter overall survival (Tenhagen et al., 2012). FGFR2 
amplifications are also found in up to 10% of gastric cancers (Kunii et al., 2008). Expression 
levels of FGFR1 and FGFR2 are frequently increased in advanced poorly differentiated 
prostate carcinomas, even though amplifications of these receptors are relatively low (Kwabi-
Addo et al., 2004). The mechanism of this upregulation has remained unclear so far. 
Amplifications of FGFR3 have been observed rarely in cancers (Nord et al., 2010). About 
10% of breast cancers display FGFR4 amplifications,  which  is  associated  with  ER  and  
progesterone receptor (PR)-positivity and lymph node metastases (Jaakkola et al., 1993). 
Importantly, increased expression of FGFR4 mRNA  in  ER-positive  breast  carcinomas  is  
associated  with  poor  clinical  benefit  with  tamoxifen  treatment  and  shorter  life  time  after  
treatment (Meijer et al., 2008).   
4.1.2.5 Aberrant?FGF?signalling??
Impaired of FGFR degradation is implicated in cancer progression. Upon ligand binding, 
activated FGFRs are intracellularly compartmentalized and degraded in lysosomes or 
proteasomes, resulting in signal termination in the physiologic context (Lemmon and 
Schlessinger, 2010; Parachoniak and Park, 2012). Several FGFR mutants disrupt the receptor 
endocytic trafficking and degradation, leading to prolonged active FGF signalling 
(Parachoniak and Park, 2012). For example, a mutation in the transmembrane domain of 
FGFR3-G380R displays prolonged active FGF signalling by high recycling rate to the plasma 
membrane surface rather than degradation (Cho et al., 2004).  
Negative regulators of FGF signalling, the Sprouty and Sef proteins are frequently down-
regulated in prostate cancer, increasing FGF signalling (Darby et al., 2006; Darby et al., 
2009; Fritzsche et al., 2006). Moreover, increased expression of FGF1, FGF2 and FGF7 has 
been detected in breast cancer stroma, which may promote tumour growth and cancer cell 
migration in a paracrine manner (Finak et al., 2008). Upregulation of both FGF2 and FGFR1 
expression in melanoma or FGF1 and FGFR1IIIc in ovarian cancer are associated with poor 
patient survival by aberrant autocrine FGF signalling activation (Marek et al., 2009; Wang 
and Becker, 1997).  
4.2 Eph?receptor?family??
The erythropoietin-producing hepatocellular (Eph) receptor family represents the largest 
family of receptor tyrosine kinases. Eph receptors have been classified into either EphA or 
EphB subfamilies based on their specific ligands. EphA receptors (EphA1-10) bind to 
glycosylphosphatidylinositol (GPI)-linked ephrinA ligands (ephrinA1-6), and EphB receptors 
(EphB1-6) to ephrinB ligands (ephrinB1-3). Exceptionally, EphA4 and EphB2 can bind to 
ephrinBs and ephrinA5, respectively, and EphB4 preferentially binds to ephrinB2 only 
(Pasquale, 2010).  
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Upon ligand binding at cell-cell contact, 
the activated Ephs trigger multiple 
downstream signalling pathways including 
PI3K-AKT, Janus kinase (JNK)-STAT, as 
well as FAK- and Src-Rho GTPases 
(Pasquale, 2008; Pasquale, 2010; Figure 
14). These downstream signalling regulate 
cytoskeletal reorganization and cell-cell or 
cell-matrix interactions depending on cell 
type-specific adaptor protein expression 
and crosstalk with other signalling 
networks,  such  as  other  RTK  signalling  
(e.g.  EGFR,  FGFR,  and  VEGFR)  and  
intracellular Akt and Ras/ERK signalling 
pathways (Miao and Wang, 2012; 
Pasquale, 2010; Figure 14). In contrast, the 
reverse signalling in ephrin expressing 
cells induces SFK-dependent signalling 
that mediates either tight junction 
assembly or Rac1-mediated cytoskeletal 
rearrangement in a tissue context-
dependent manner (Pasquale, 2010). The 
Eph/ephrin complexes are subsequently 
removed from cell-cell contact sites by endocytosis into ephrin expressing or Eph expressing 
cells (Janes et al., 2012; Pasquale, 2005). For example, ADAM10 cleaves receptor-bound 
ephrin ligand and releases Eph/ephrin complexes from the ligand-expressing cells, which is 
followed by endocytosis and ultimately cell-cell  repulsion (Hattori  et  al.,  2000; Janes et  al.,  
2005; Janes et al., 2009). The ADAM10 substrate sequence is highly conserved in the 
extracellular domain of all ephrins. Therefore the proteolytic regulation of ephrin/Eph 
complexes is a general phenomenon that regulates cell behaviour (Janes et al., 2012).  
4.2.2 EphA2?in?cancer?
EphA2 is one of the best-studied Eph receptors in physiological and pathological conditions 
during the last decade. EphA2 is known as a tumour-suppressor, which cooperates with E-
cadherin to maintain epithelial cell-cell junctions and apicobasal cellular polarity (Miura et 
al., 2009; Zantek et al., 1999). Aberrant expression and signalling of EphA2 have been 
implicated in cancer progression and poor prognosis of cancer patients (Pasquale, 2010). 
4.2.2.1 Overexpression?
EphA2 is frequently overexpressed in many types of cancer including breast, prostate, 
ovarian, pancreatic, colon and lung carcinomas as well as melanoma and glioblastoma 
multiforme (Brantley-Sieders, 2012; Margaryan et al., 2009; Wykosky and Debinski, 2008). 
Overexpressed EphA2 is often associated with aggressive cancer progression and poor 
prognosis (Brantley-Sieders, 2012; Wykosky and Debinski, 2008). In breast cancer and 
Figure 14. EphA signalling network.  
(EphA signalling) Ligand binding at cell-cell 
contacts triggers ligand and receptor clustering 
and tyrosine phosphorylation (yellow) in 
juxtamembrane and TK domains, leading to 
“forward” downstream signalling cascades, e.g. 
PI3K-AKT, JNK-STAT, FAK, and Src (light blue). 
The “reverse” signalling through the ephrins can 
also be generated.  (EphA crosstalk) The activated 
Akt, by other RTK signalling phosphorylates 
EphA2 on serine residue (orange), leading to 
Ras/ERK signalling and Rho-GTPase activation.  
(Adapted and modified from Pasquale, 2010) 
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glioblastoma, overexpression of EphA2 is often correlated with low expression level of its 
cognate ligand, ephrinA1 (Macrae et al., 2005; Wykosky et al., 2005). This imbalanced 
expression pattern of ligand and receptor in breast carcinoma cells is induced by the 
activation of Ras/ERK signalling, which is induced by other RTK signalling pathways 
(Macrae et al., 2005). Overexpressed EphA2 molecules on the cell surface can spontaneously 
associate with each other. So far this self-assembly mechanism is not fully confirmed 
(Himanen et al., 2007; Nievergall et al., 2011).   
In normal epithelial cell layers, EphA2 signalling cooperates with E-cadherin-mediate 
epithelial cell-cell adhesion (Miura et al., 2009; Zantek et al., 1999). E-cadherin expression 
induces EphA2 localization at cell-cell junctions and increases ligand-dependent EphA2 
signalling. The activated EphA2 in turn enhances E-cadherin-based cell-cell adhesion, 
apicobasal cellular polarity, and inhibition of actin cytoskeleton remodelling (Miura et al., 
2009; Zantek et al., 1999). Overexpressed EphA2 in cancer cells disturbs epithelial adherens 
junctions through upregulation of Src-RhoA signalling (Fang et al., 2008; Miao et al., 2000; 
Parri et al., 2007; Zelinski et al., 2001). These signalling lead to suppression of integrin-
mediated cell-matrix adhesion, which triggers cell-cell and cell-matrix junction disassembly 
and cell rounding (Fang et al., 2008; Miao et al., 2000; Parri et al., 2007; Zelinski et al., 
2001). Increased RhoA activity also induces actomyosin contractility-driven amoeboid-type 
cell invasion (Parri et al., 2009; Taddei et al., 2011).  
4.2.2.2 Ligand-independent?signalling??
In advanced glioblastoma, breast and prostate carcinoma cells, the overexpressed EphA2 can 
cooperate with other RTK signalling in ligand-independent manner and act as a potential 
guidance molecule for collectively migrating cells (Miao and Wang, 2012). In the presence of 
the ligand, the activated EphA2 inhibits integrin-Rac-mediated cell migration/invasion and 
cell proliferation, accompanied by suppression of Akt-mTORC1 activities (Miao et al., 2000; 
Miao et al., 2009; Yang et al., 2011). In contrast, other RTK signalling, e.g. EGF signalling 
activates Akt that phosphorylates ligand-unbound EphA2 on a serine residue (Ser at 897) that 
promotes glioblastoma and metastatic prostate carcinoma cell migration/invasion (Miao et al., 
2009). This serine phosphorylated EphA2 can be used as a biomarker for stratification of 
patients carrying brain and prostate tumours, since oncogenic Akt activation coupled with 
PTEN-loss is correlated with higher grade of these tumours (Miao and Wang, 2012; Parsons 
et al., 2008; Tomlins et al., 2007). This cross-talk is also observed in invasive breast 
carcinoma cells wherein EGF signalling enhances cell migration and EphA2 expression 
through Ras/ERK signalling, whereas ligand binding down-regulates EphA2 levels by 
inducing receptor internalization and degradation (Hiramoto-Yamaki et al., 2010; Macrae et 
al., 2005). 
EphA2 overexpression can play a role in both intrinsic and acquired resistance to anti-HER2 
antibody trastuzumab-based therapy that is used as an initial treatment for HER2 positive 
breast cancer patients (Zhuang et al., 2010). The cross-talk signalling with other RTK may be 
a one mechanism of cancer therapy resistance. 
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4.2.2.3 SNPs?and?Mutations?
Human genome sequencing studies have revealed numerous EphA2 SNP variants and 
somatic mutations (Greenman et al., 2007; Jun et al., 2009; Park et al., 2012; Shiels et al., 
2008; Zhang et al., 2009). Several of SNPs are related to human cataract (Jun et al., 2009; 
Park et al., 2012; Shiels et al., 2008; Zhang et al., 2009). One of the somatic mutations 
identified  from human cancer  genomes  has  Gly  to  Arg  replacement  in  the  first  FN domain  
(EphA2-G391R) (Faoro et al., 2010; Greenman et al., 2007). The EphA2-G391R was found 
in lung squamous cell carcinoma patient samples. This mutant increases cell growth and 
migration by focal adhesion assembly through increased EphA2 kinase activity coupled with 
Src, cortactin, and p130Cas downstream signalling activation (Faoro et al., 2010).    
4.3 FGF?and?Eph?signalling?in?cancer?cell?invasion?
Both cancer-associated FGF and Eph signalling contribute to cancer progression. Besides 
controlling cell proliferation and survival, these signalling promote cancer cell invasion and 
metastasis through regulating cytoskeletal dynamics and modulating cell-cell and cell-ECM 
communications (Friedl and Alexander, 2011; Lemmon and Schlessinger, 2010).  
4.3.1 FGF?signalling?in?cancer?cell?invasion?
FGF signalling can promote cell migration/invasion in several ways (Turner and Grose, 
2010). For example, synthetic ligand-inducible FGFR1 (iFGFR1) signalling triggers 
transformations of epithelial-type prostate and breast cancer cells into motile mesenchymal 
phenotypes in vitro and in vivo (Acevedo et al., 2007; Welm et al., 2002; Xian et al., 2007). 
iFGFR1 signalling in transgenic mice further induces apoptosis-resistance by activating 
MAPK and Akt signalling pathways, resulting in formation of multicellular lesions in 
prostate and mammary epithelium that ultimately become invasive (Acevedo et al., 2007; 
Welm et al., 2002). In mesenchymal-type cells, FGFR forms a complex with a cell-cell and 
cell-matrix  adhesion  molecule,  NCAM at  the  cell  surface  (Cavallaro  et  al.,  2001).  Through 
the complexes, NCAM stabilizes activated FGFR at invasive edges of tumours, leading to 
focal adhesion- and Rac1-mediated cancer cell invasion (Francavilla et al., 2007; Francavilla 
et al., 2009; Lehembre et al., 2008; Zecchini et al., 2011). Furthermore, an activation of 
FGF10-FGFR2 IIIb signalling in pancreatic carcinomas up-regulates MT1-MMP expression 
and promotes cancer invasion (Nomura et al., 2008). 
FGFR4-G388R SNP is associated with aggressive cancer cell migration/invasion (Bange et 
al., 2002; Seitzer et al., 2010; Stadler et al., 2006; Wang et al., 2004). The homo- or 
heterozygous FGFR4-R388 variants are present in approximately 50% of Caucasian and 
Asian human population, while this variant bearing African American population is relatively 
low (approximately 20-30% of population; Bange et al., 2002; Wang et al., 2004; Xu et al., 
2011). The FGFR4-R388 variant significantly increases prostate cancer risk in Caucasian and 
Asian (Ma et al., 2008; Wang et al., 2004; Xu et al., 2011), while this risk variant is rather 
correlated with aggressive cancer progression and poor prognosis of patients with many types 
of cancer including breast, prostate, and lung carcinomas (Bange et al., 2002; Spinola et al., 
2005; Wang et al., 2004). To date, several cellular and molecular mechanisms of FGFR4-
R388 variant-associated breast and prostate carcinoma cell migration/invasion have been 
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reported. This risk variant increases kinase activity in mammary tumours in transgenic mice 
carrying FGFR4-R385 and in prostate carcinoma cells, suggesting that the cancer-promoting 
potential of the FGFR4-R388 risk variant is possibly due to an enhanced kinase activity 
(Seitzer et al., 2010; Wang et al., 2008). This variant expression also induces upregulation of 
pro-migratory and pro-invasive genes including MMPs and downregulation of tumour 
suppressor genes (Seitzer et al., 2010; Stadler et al., 2006; Yu et al., 2011). In breast 
carcinoma cells, plasminogen activator inhibitor (PAI-1) expression is suppressed by the 
FGFR4-R388 risk variant expression, resulting in upregulation of urokinase plasminogen 
activator (uPA). Upregulation of uPA is linked to increase cell migration and invasion as well 
as decrease the sensitivity of the FGFR4-R388-expressing cells to chemotherapy-induced 
apoptosis (Whitley et al., 2004). In prostate carcinoma cells, upon ligand binding the stability 
of the activated FGFR4-R388 variant is increased and thus FGF signalling is prolonged 
(Wang et al., 2008). Enhanced FGFR kinase activity increases ERK/MAP signalling and 
transcription of pro-invasive genes, promoting prostate carcinoma cell invasion and 
metastasis (Wang et al., 2008; Yu et al., 2011). Thus, the kinase activities and downstream 
targets of the FGFR4-R388 variant seem to increase cancer cell invasion and decrease 
sensitivity to adjuvant chemotherapy, explaining the worse clinical outcome of carriers with 
this risk variant (Tenhagen et al., 2012).  
4.3.2 Eph?signalling?in?cancer?cell?invasion?
Cancer cell dissemination from a primary tumour mass, as well as unimpeded migration and 
invasion through stromal space are important steps for metastatic cancer progression. Eph 
receptors and their membrane-anchored ligands, ephrins are located at cell-cell contact sites 
and directly regulate both cancer cell- cancer cell (homotypic) and cancer cell-stromal cell 
(heterotypic) interactions (Astin et al., 2010). Recently Astin and his colleagues reported that 
PC3 prostate cancer cells in vitro interchange between homotypic repulsion and heterotypic 
attraction  by  using  different  sets  of  Eph  receptors  and  ligands  on  cancer  cells  and  stromal  
cells (Astin et al., 2010). PC3 cells express both endogenous EphA and EphB receptors 
(EphA2, EphA4, EphB3, and EphB4) and ephrinA ligands, while fibroblasts express ephrinA 
and ephrinB ligands. Upon homotypic PC3 cell collision, EphA receptors are trans-activated 
by endogenous ephrinA ligands on the opposing cells (Astin et al., 2010). The activated 
EphA2 and EphA4 trigger repulsive cell movement by causing retraction of membrane 
protrusions and reinitiation of migration in a different direction through RhoA activation at 
the colliding sites (Astin et al., 2010; Figure 15A). However, heterotypic contacts between 
PC3 and fibroblasts triggers EphB-ephrinB signalling that can override EphA-ephrinA 
signalling and induces filopodia and lamellipodia formation through Cdc42 activation, 
resulting in unimpeded migration to the stromal space (Astin et al., 2010; Figure 15B). Thus 
EphB-ephrinB system can contribute to guidance of prostate cancer cell invasion into 
surrounding tissues, while EphA signalling contributes to cancer cell dissemination (Astin et 
al., 2010). 
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5 Matrix?Metalloproteinases??
Cancer cell invasion drive aggressive cancer progression and poor prognosis of patients with 
many types of cancer. As described above, cancer-associated FGF and Eph signalling are 
involved in these processes. Important players for tumour expansion and metastatic cancer 
progression are MT-MMPs that regulate ECM remodelling by cleaving components of 
interstitial tissues and BMs. They also regulate cellular behaviour by modulating numerous 
intracellular signalling pathways through interacting with cell surface signalling receptors and 
intracellular cytoskeleton components. 
 MMPs are zinc-dependent endopeptidases composed of 23 members in vertebrates that 
consist of 16 soluble MMPs (MMP1-3, 7-13, 19-22, 27, and 28) and 7 membrane-anchored 
MMPs (MMP14-17, and 23-25; also termed MT1-MT6-MMP and MMP23) (Kessenbrock et 
al., 2010; Figure 16). They share a common structure, consisting of a pro-peptide, a catalytic 
domain, and a hemopexin-like domain that is linked to the catalytic domain via a flexible 
hinge region (Kessenbrock et al., 2010; Figure 16). Type I transmembrane MT-MMPs, MT1-
MT3-MMP (MMP14-16), and MT5-MMP (MMP24), have a single transmembrane domain 
followed by a short cytoplasmic tail, whereas MT4-MMP (MMP17) and MT6-MMP 
(MMP25) are anchored into the plasma membrane by GPI-linker and MMP-23 is a type-II 
transmembrane MT-MMP that has  unique cysteine array (CA) and immunoglobulin (Ig)-like 
domains (Kessenbrock et al., 2010; Figure 16).  
MMPs are expressed in pro-forms that are kept enzymatically inactive by interaction between 
a  cysteine  residue  of  the  pro-peptide  domain  and  the  zinc  ion  of  the  catalytic  domain.  The  
pro-peptide domain is removed by a proteolytic process, which generates catalytically active 
enzymes. The cleavage occurs intracellularly by a serine protease, furin, or extracellularly by 
other MMPs or other serine proteinases, such as plasmin (Kessenbrock et al., 2010).  
5.1 MT-MMPs?
MT1-MMP is a potent ECM remodelling enzyme that was the first reported type I 
transmembrane MT-MMP (Sato et al., 1994). To date, other five MT-MMPs, MT2-MMP 
(Will and Hinzmann, 1995), MT3-MMP (Takino et al., 1995), MT4-MMP (Puente et al., 
Figure 16. Structure of MMPs. (Adapted and modified from Egeblad and Werb, 2002) 
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vitronectin, aggrecan, and fibrin (Itoh and Seiki, 2006; Table 1 and Figure 17). MT1-MMP is 
expressed at the leading edge of leader cells of collective cell cohort and mensenchymal-type 
singly-invading cells. The proteolytic activity of this enzyme assists in forming de-novo gaps 
and micro-tracks for cancer invasion (Friedl and Alexander, 2011; Sabeh et al., 2009; Wolf et 
al., 2007). Unlike MT1-MMP, MT3-MMP does not degrade cross-linked collagen efficiently 
(Li and Zhu, 2010; Sabeh et al., 2004; Shimada et al., 1999). MT3-MMP rather cleaves 
fibrin, and importantly this enzyme reduces MT1-MMP expression on the cell surface 
(Hotary et al., 2002; Tatti et al., 2011; Table 1). 
By cleaving ECM components, MMPs generate biologically functional ECM fragments that 
can promote cell-matrix adhesion or cell migration (Kessenbrock et al., 2010; Page-McCaw 
et al., 2007). For example, ?2 and ?3 subunit fragments of laminin 5 cleaved by MT1-MMP 
promote cell migration and invasion in vitro and in vivo (Giannelli et al., 1997; Gilles et al., 
2001; Hamasaki et al., 2011; Koshikawa et al., 2000; Udayakumar et al., 2003). MMPs also 
release ECM-bound growth factors and cytokines, e.g. EGF (Koshikawa et al., 2011), TNF-
??(Tam et al., 2004), and LTBP-bound TGF-? (Mu et al., 2002; Tatti et al., 2008; Figure 17), 
and thus increase the bioavailability of these soluble factors in extracellular milieu. 
Furthermore, MMPs can also modulate the activities of growth factors and cytokines by 
cleavage, e.g. ?1-proteinase inhibitor inactivation (?1-PI; Kataoka et al., 1999), IL-8 and 
CXCs degradation (Tam et al., 2004; Dean et al., 2008; Tam et al., 2004; Table 1).  
On the cell surface, MT-MMPs regulate activities of soluble-type MMPs and the related 
metzincin proteases, a disintegrin and metalloproteinase (ADAM) and a disintegrin and 
metalloproteinase with thrombospondin motifs (ADAM-TS) (Chan et al., 2012; Kessenbrock 
et al., 2010; Rodriguez-Manzaneque et al., 2000). For examples, MT1-MMP is a main 
activator for latent-type MMP2 (Lehti et al., 1998; Sato et al., 1996b). Tissue inhibitor of 
metalloproteinases 2 (TIMP2) can assist in this process. The catalytic domain of MT1-MMP 
binds to the N-terminal domain of TIMP2 and the C-terminal domain of TIMP2 binds to the 
hemopexin domain of proMMP2, forming an MT1-MMP-TIMP2-MMP2 complex (Strongin 
et al., 1995). The N-terminal pro-peptide domain of proMMP2 is cleaved by a TIMP2-free 
adjacent MT1-MMP, generating an active form of MMP2 (Itoh et al., 2001; Lehti et al., 
2002; Sato et al., 1996b). MT1-MMP also activates proMMP13 and inhibits ADAM9 activity 
by shedding it (Chan et al., 2012; Figure 17).  
Furthermore, MT1-MMP mediates cellular functions by modulating many intracellular 
signalling pathways through interacting and cleaving cell surface adhesion molecules, e.g. 
CD44 (Kajita et al., 2001), low-density lipoprotein receptor related protein (LRP1; Lehti et 
al., 2009; Rozanov et al., 2004), ?v integrin (Deryugina et al., 2002), and syndecan-1(Endo et 
al., 2003; Table 1 and Figure 17), promoting cancer cell motility. Interestingly, MT1-MMP 
forms  complexes  with  PDGFR??and?FGFR??on the cell surface, which can indirectly 
modulate these RTK signalling activities by cleaving their co-factors, LRP1 and ADAM9, 
respectively (Chan et al., 2012; Lehti et al., 2005; Lehti et al., 2009; Figure 17). The short 
cytoplasmic domains of MT-MMPs can associate with cytoskeleton components, promoting 
cell invasion through confined MT1-MMP localization at invasive membrane protrusions 
(Nakahara et al., 1997; Poincloux et al., 2011). Furthermore, phosphorylation of a tyrosine 
residue (Tyr at 573) in MT1-MMP cytoplasmic domain by non-receptor tyrosine kinase, Src 
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is also essential for effective cancer cell invasion (Labrecque et al., 2004; Moss et al., 2009; 
Nyalendo et al., 2007; Nyalendo et al., 2008; Figure 17).  
Although the substrates of MMPs overlap, the specificity of substrate for individual MMPs 
relies on the sequence of their catalytic domains (substrate-binding pocket) that recognize the 
exposed specific substrate sequence (Overall, 2002). MMPs bind to the specific substrates 
and inhibitors through exosites located on the hemopexin domain (Overall, 2002). The 
interaction of MMP and their substrates is also supported by binding through hinge region 
(Osenkowski et al., 2005). 
5.1.2 Regulation?of?MT-MMP?activity?
Due to the multiple functions of MT-MMPs within pericellular microenvironment, their 
temporal and spatial expression, activation, and localization are tightly controlled by both 
transcriptional and posttranscriptional processes (Egeblad and Werb, 2002; Kessenbrock et 
al., 2010).  
5.1.2.1 Transcriptional?regulation??
Transcriptional regulation of MMP expression is mediated by several growth factor/cytokine 
signalling pathways. These signalling pathways associated with the induction of EMT (e.g. 
TGF-?,  Wnt,  and  TNF-?)  can  trigger  the  expression  of  MT1-MMP and  other  ones  such  as  
MMP3, MMP7, MMP9, and MT2-MMP (Blavier et al., 2006; Labbe et al., 2007; Ottaviano et 
al., 2006; Takahashi et al., 2002; Udayakumar et al., 2003). E-cadherin repressor, Snail and 
hNanos1 can up-regulate MT1-MMP, and the expressed MT1-MMP cleaves E-cadherin and 
eventually dissociates E-cadherin-mediated adherence junctions (Bonnomet et al., 2008; 
Miyoshi et al., 2004). Phorbol 12-myristate 13-acetate (PMA) and concanavalin A treatment 
also induces MT1-MMP transcription  (Lohi  et  al.,  1996).  Moreover,  in vivo and  within  3D 
collagen matrix type I collagen induces cell-surface MT1-MMP expression transcriptionally 
through TGF-? signalling (Ottaviano et al., 2006; Sakai et al., 2011; Shields et al., 2011).  
Figure 17. Biological functions of MT1-MMP. These functions promote cancer cell 
invasion and migration. (Adapted and modified from Ito and Seiki, 2006). 
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5.1.2.2 MMP?inhibitors?
The MMP activities on the cell surface or in the extracellular milieu are constantly controlled 
by the endogenous MMP inhibitors. The major inhibitor in tissue fluid is the abundant plasma 
protein ?2-macroglobulin (?2-MG), which efficiently binds to the active site of MMPs. The 
complexes of ?2-MG-MMP are then bound to scavenger receptors and irreversibly cleared by 
endocytosis (Kessenbrock et al., 2010). A reversion-inducing-cysteine rich protein with 
Kazal  motifs  (RECK)  also  inhibits  MT-MMPs  and  MMP2  proteolytic  activities  (Oh  et  al.,  
2001).  
The most potent MMP inhibitors are tissue inhibitors of metalloproteinases (TIMPs). They 
are secreted proteins that reversibly bind to MMPs at a 1:1 ratio and inhibit their activities 
(Brew and Nagase, 2010; Lambert et al., 2004). Unlike ?2-MG, four members of TIMPs 
(TIMP1-4) are expressed in specific tissues and have different binding specificities to 
individual MMPs, as well as ADAMs and ADAMTSs (Lambert et al., 2004). The C-terminal 
domain of TIMP2 binds to the hemopexin domain of the proenzyme of MMP2, which is 
essential for the cell surface MMP2 activation by MT1-MMP (Strongin et al., 1995). TIMPs 
2-4 bind to soluble MMPs and MT-MMPs, whereas TIMP1 has more restricted specificity 
and does not bind to MT-MMPs (Lambert et al., 2004). The balance of activities between 
TIMPs and MMPs are important for tissue homeostasis. Therefore, the disruption of this 
balance can be implicated in cancer progression.  
5.1.2.3 Intracellular?trafficking?and?cell-surface?localization?of?MT-MMPs?
The localization and compartmentalization of MMPs are important for temporal and spatial 
restriction of biological MMP activities. The localization of MMPs to specific sites of plasma 
membrane is regulated by exocytotic transportation and interaction with cytoskeleton or cell 
surface receptors such as integrins (Poincloux et al., 2009; Rowe and Weiss, 2009). This 
increases their concentration and proteolytic activities in the limited pericellular environment 
and may also allow escaping from accessibility of their inhibitors (Kessenbrock et al., 2010). 
Confined localization of MT-MMPs and several soluble type MMPs on the invasive 
membrane protrusions is critical for their ability to drive cell invasion (Bourguignon et al., 
1998; Brooks et al., 1996; Hotary et al., 2000; Rupp et al., 2008).  
In  the  case  of  MT1-MMP,  the  expressed  ~63  kDa  proMT1-MMP  is  converted  to  a  
catalytically active enzyme (~60 kDa) by furin cleavage in trans-Golgi network (TGN) prior 
to trafficking to the cell surface (Lehti et al., 1998; Mazzone et al., 2004; Sato et al., 1996a; 
Yana and Weiss, 2000). Following activation, MT1-MMP is translocated to intracellular 
Rab8-positive exocytotic vesicles that actively transport MT1-MMP to invasive membrane 
protrusions, such as invadopodia (Bravo-Cordero et al., 2007; Figure 18). Invadopodia is a 
small dot-shaped actin-based invasive structure on the basal surface of invading cells, where 
cell-ECM adhesion molecules (e.g. integrin), tyrosine kinases (e.g. FAK and Src), actin-
assembly regulators (e.g. cortactin and Arp2/3) and proteases are concentrated (Murphy and 
Courtneidge, 2011; Poincloux et al., 2009; Rowe and Weiss, 2009). Rho-GTPases mediate 
polarized trafficking of MT1-MMP-containing vesicles to invadopodia (Itoh et al., 2008; Itoh 
et al., 2011; Sakurai-Yageta et al., 2008). The vesicles are then fused to invadopodial 
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membranes and MT1-MMP is ultimately located to the tip of the protrusion structure through 
the interaction with ?1integrin and cortactin (Murphy and Courtneidge, 2011; Poincloux et 
al., 2009; Rowe and Weiss, 2009). Soluble-type MMP2 and MMP9 are also specifically 
located at invadopodia, where MMP2 binds to integrin ???3 (Brooks et al., 1996; Rupp et al., 
2008) and MMP9 to CD44 (Bourguignon et al., 1998). The accumulated MT1-MMP can 
activate latent-type MMP2 in these structures, amplifying pericellular proteolytic activities 
and promoting cancer cell invasion (Lehti et al., 1998; Sato et al., 1996b; Rupp et al., 2008). 
On the cell surface, MT1-MMP activity is further regulated by proteolytic shedding, 
autocatalytic inactivation, endocytosis, and exosome secretion (Hakulinen et al., 2008; Jiang 
et al., 2001; Lehti et al., 1998; Lehti et al., 2000). The  ~60 kDa active MT1-MMP on the cell 
surface forms a homo-oligomer via hemopexin domain and/or transmembrane domain (Itoh 
et al., 2001; Itoh et al., 2008; Lehti et al., 2002). Within the oligomers, the active form of 
MT1-MMP is subsequently autocatalytically processed to ~43 kDa form that lacks the 
catalytic domain (Lehti et al., 1998; Lehti et al., 2000; Stanton et al., 1998; Toth et al., 2002). 
The appearance of this catalytically inactive form can be an indication of functional activity 
of MT1-MMP on the cell surface, since a high level of ~43kDa form coincides with high 
proMMP2 activation (Lehti et al., 1998; Stanton et al., 1998). MT1-MMP is also able to be 
processed within hemopexin domain and in stem region (between hemopexin and 
transmembrane domains), resulting in soluble functional ~50kDa, ~40kDa, and ~32kDa 
fragment generation in extracellular milieu (Toth et al., 2002; Toth et al., 2005).   
Cell surface MT1-MMP is constantly compartmentalized into intracellular endosomes. This 
event is regulated by both clathrin- and caveolae-dependent pathways (Jiang et al., 2001; 
Labrecque et al., 2004; Remacle et al., 2003; Uekita et al., 2001; Zucker et al., 2002; Figure 
18). By endocytosis, the inactivated MT1-MMP is cleaned from cell surface (Maquoi et al., 
2000; Zucker et al., 2002; Figure 16). A dileucine motif, LLY sequence in the cytoplasmic 
tail of MT1-MMP is a functional binding site for the AP-2-clathrin adaptor complex (Uekita 
et  al.,  2001).  Phosphorylation  of  this  tyrosine  (Tyr  at  573)  by  Src  is  essential  for  clathrin-
dependent MT1-MMP endocytosis (Nyalendo et al., 2007). Of note, impaired MT1-MMP 
phosphorylation stabilizes MT1-MMP on the cell surface, leading to induction of EMT, 
activation of ovarian cancer cell invasion, and reduction of cell proliferation within 3D 
collagen  matrix  (Moss  et  al.,  2009).  The  cytoplasmic  tail  of  MT1-MMP  can  also  associate  
with caveolin-1 in the lipid-rafts on cancer cells and endothelial cells (Annabi et al., 2001; 
Galvez et al., 2004; Remacle et al., 2003). MT1-MMP is thus endocytosed by caveolae-
dependent pathway (Labrecque et al., 2004; Remacle et al., 2003) 
The internalized MT1-MMPs are then transported to lysosomal degradation or recycling 
compartments that potentially relocate to the plasma membrane (Remacle et al., 2003; Wang 
et al., 2004; Figure 18). MT1-MMP recycling via TGN requires the presence of DKV motif 
in its cytoplasmic domain, and EWV motif for other MT2, MT3, and MT5-MMPs (Wang et 
al., 2004). Taken together, the newly synthesized MT1-MMP and recycled pre-existing MT-
MMPs are actively delivered to invadopodia and other invasive membrane protrusion, where 
they can play proteolytic activities and further drive cell invasion (Poincloux et al., 2009). 
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al., 2001). Consistently, PDGF signalling is attenuated in MT1-MMP knockout mice (Lehti et 
al., 2005). MT1-MMP associates with PDGFR???integrin ??? and  LRP1  on  the  same  
membrane surface of vascular smooth muscle cells, promoting PDGF-BB-induced signalling 
via the receptor by cleaving a negative regulator of PDGFR signalling, LRP1. Through this 
complex MT1-MMP regulates vessel wall architecture maturation and vascular smooth 
muscle cell dedifferentiation in vivo (Lehti et al., 2005; Lehti et al., 2009). Interestingly, 
MT1-MMP deficient mice also display similar phenotypes with FGF signalling mutants, e.g. 
defective calvarial bone growth in FGF18 knockout mice (Liu et al., 2002; Ohbayashi et al., 
2002). Recently, it was reported that MT1-MMP forms a complex with ADAM9 and FGFR2 
on the cell surface in osteoblasts and proteolytically inhibits ADAM9 activity, which sustains 
FGFR signalling by protecting of FGFR2 from ADAM9-mediated cleavage and rescues 
calvarial osteogenesis (Chan et al., 2012). Therefore, MT1-MMP indirectly modulates PDGF 
and FGF receptor tyrosine kinase signalling pathways by cleaving their co-factors in the same 
protein complexes on the cell surface in vivo (Chan et al., 2012; Lehti et al., 2005; Lehti et 
al., 2009).  
5.2.1.2 MT1-MMP?in?cancer?cell?invasion?and?metastasis?
Some studies using in vitro cross-linked collagen matrix and in vivo mouse xenograft 
revealed that ectopic overexpression of MT1-MMP accelerates the invasive growth of poorly 
invasive squamous cell carcinoma cells (SCCs; Hotary et al., 2003). Conversely, fibroblasts 
and invasive human fibrosarcoma cells (HT-1080) that normally express high levels of MT1-
MMP fail to invade into thick cross-linked collagen matrix after MT1-MMP knockdown 
(Sabeh et al., 2004; Sabeh et al., 2009). Inhibition of MT1-MMP by a monoclonal antibody 
blocks breast carcinoma cell growth, invasion, and angiogenesis in a mouse xenograft model 
(Devy et al., 2009). Together, these studies suggest that this protease plays multifaceted 
critical roles in malignant cancer progression.   
Upregulation of MT1-MMP is frequently observed in many types of human cancer, where 
MT1-MMP expression is induced at invasive edges of tumours and reactive stroma (Okada et 
al., 1995; Szabova et al., 2005). In invasive carcinoma cells, MT1-MMP is associated with ?1 
integrin in invadopodia or other invasive protrusive structures that interact with collagen 
fibres along the leading edge, where both cell traction and ECM degradation take place to 
drive mesenchymal-type cancer cell invasion (Packard et al., 2009; Wolf et al., 2007). When 
MT1-MMP activity is inhibited by inhibitors or gene knockdown, cancer cells can switch 
their invasive machinery from a protease-dependent mesenchymal phenotype to a protease-
independent amoeboid-type phenotype that is driven by RhoA-mediated actomyosin 
contractility (Sabeh et al., 2009; Wolf et al., 2003). The population of amoeboid-type 
invading cells are minor, but observed in many types of tumour. They infiltrate rapidly 
through pre-existing matrix-free spaces that are generated by proteolytic activities of cancer-
associated stromal cells or by aberrant ECM metabolism (Levental et al., 2009; Sabeh et al., 
2009; Sanz-Moreno and Marshall, 2010; Wolf et al., 2003; Wolf and Friedl, 2011). For 
example, the activated CAFs express MT1-MMP to degrade adjacent ECM components and 
generate matrix-free micro-tracks which can be utilized by collective carcinoma cell invasion 
and protease-independent cell invasion (Chaudhry et al., 2013; Gaggioli et al., 2007).  
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Besides adjacent ECM degradation, MT1-MMP can promote cancer-associated new blood 
vessel formation in a paracrine manner by increased pro-angiogenic VEGF-A expression in 
carcinoma cells through Src, Akt, and mTOR signalling activation (Eisenach et al., 2010; 
Sounni et al., 2004). On endothelial cells, MT1-MMP sheds and decreases membrane-
anchored Tie-2 receptor levels, resulting in vessel destabilization and subsequent endothelial 
migration (Onimaru et al., 2010), whereas endoglin cleavage inhibits angiogenesis 
(Hawinkels et al., 2010). Cleavage of LTBP by MT1-MMP in perivascular stroma increases 
TGF-? bioavailability and its signalling via the cell-surface receptors on endothelial cells, 
leading to new vessel formation (Sounni et al., 2011; Tatti et al., 2008). Cancer-associated 
vessels are immature and highly permeable. These circulation systems can be thus used as 
matrix-free passage-way for metastatic cancer cells. 
Taken together, the membrane-anchored MT1-MMP can function in sequestered pericellular 
microenvironment to drive cancer cell invasion and metastasis. By cleaving adjacent ECM 
components, MT1-MMP promotes cancer cell invasion through basement membrane and 
native cross-linked fibrillar collagen matrices. This collagenolytic activity also provides 
poorly cross-linked reconstituted environment that allows cells to rapidly migrate by 
squeezing through small spaces within matrix. Furthermore, by activation of pro-angiogenic 
signalling, MT1-MMP promotes angiogenesis and further facilitates cancer cell 
dissemination from a primary tumour to distant organs. Therefore, understanding of the 
molecular mechanisms of this multi-functional protease may help to develop strategies for 
efficient clinical interventions for cancer patients.  
 ?
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AIMS?OF?THE?STUDY?
Cancer cell invasion includes orchestrated processes that are driven by protein kinase 
signalling and pericellular protease activities. Membrane-type1 matrix metalloproteinase 
(MT1-MMP) plays multifaceted critical roles in cancer cell invasion and metastasis. In 
sequestered pericellular microenvironment, this protease potently regulates pericellular ECM 
remodelling and modulates motile cell behaviour by cooperating with numerous protein 
kinase signalling pathways. The main aim of this study was to define upstream or cooperating 
protein kinase signalling that regulate pro-invasive MT1-MMP activities in cancer 
progression. I first carried out a screen to identify cellular kinases that are involved in MT1-
MMP function in cancer cell invasion. Among the identified novel MT1-MMP regulators I 
focused on FGFR and EphA2, since the cell surface receptor kinases can be potential 
therapeutic targets for patients with cancer. Therefore, I continued to explore cooperative 
molecular mechanisms linking cancer-associated FGFR and Eph receptor tyrosine kinase 
signalling to the pro-invasive activities of MT1-MMP.  
The specific aims of this study were:   
1) To identify cancer-associated upstream and co-operative signalling kinases for pro-
invasive MT1-MMP activities and cancer cell invasion. 
 
2)  To define the molecular mechanisms of co-operating fibroblast growth factor receptor-
4 (FGFR4) signalling with MT1-MMP in cancer progression. 
 
3) To define how the MT1-MMP-EphA2 axis regulates cell-cell communications and 
different invasion modes in cancer. 
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MATERIALS?AND?METHODS?
The methods used in this study are described in “Materials and Methods” section of each 
original publication I, II, and III. The experimental procedures that required laboratory 
animal usage were approved by the State Provincial Office of Southern Finland and 
performed according to ethical guidelines of European Convention.  
1 Methods?used?in?this?study?
 
Method: Used in: 
3-dimentional type I collagen invasive growth assay  II, III 
3-dimentional type I collagen invasion assay I, II, III 
cell surface biotinylation assay I, III 
FGFR4 allele genotyping from cultured cells, human skin samples, and human 
breast carcinoma samples 
I, II 
fluorescent-labelled matrix degradation assay I 
gelatin zymography  I, III 
gene expression database analysis (gene sapiens) II 
gene knockdown by RNA interference  I, II, III 
histology II, III 
immunoblotting I, II, III 
immunofluorescence of cultured cells and tissues I, II, III 
immunohistochemistry II, III 
immunoprecipitation I, III 
kinase screen I 
mammalian cell culture I, II, III 
mass spectrometry  III 
microscopy (epifluorescence and confocal microscopy) I, II, III 
plasmid cDNA mutagenesis I, III 
real-time quantitative PCR (qPCR) I, II, III 
Rho-GTPases activity assay III 
RNA extraction and reverse transcription I, II, III 
SDS-PAGE I, II, III 
statistical analysis I, II, III 
time-laps imaging and cell detachment and cell-cell repulsion analyses III 
transfection of cells I, II, III 
xenograft  tumour  growth  of  human  breast  and  prostate  carcinoma  cells  in  
mouse 
II, III 
2 Cell?culture?and?reagents?(I,?II,?III)?
All mammalian cells were grown in Dulbecco´s modified Eagle´s medium (DMEM), 
Minimal Eagle´s essential medium (MEM), or RPMI-1640 medium containing 10 % (v/v) 
heat inactivated fetal bovine serum (FBS), 100 U/ml penicillin G, 100 ?g/ml streptomycin, 
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was quantified using TaqMan Universal PCR Master Mix and validated Taqman® primers 
(MT1-MMP, Hs 01037006_gH; FGFR4, Hs00242558_m1; EphA2, Hs00171656_m1, 
ephrinA1, Hs00358886_m1; Applied Biosystems). The expression was normalized with 
TATA-binding protein (TBP) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) RNA 
expression.  
9 Gelatine?zymography?(I)?
Cells were cultured in complete medium for 20 h in serum-free medium. The conditioned 
media were collected and polypeptides in the medium were separated under non-reducing 
conditions using 10% SDS-polyacrylamide gels containing 1 mg/ml of gelatin. The gels were 
washed twice with 50 mM Tris-HCl buffer, pH 7.6, containing 5 mM CaCl2, 1 ?M ZnCl2 
and 2.5% Triton X-100 for 15 min to remove SDS, followed by a brief rinsing in washing 
buffer without Triton X-100. Next, the gels were incubated at 37 °C for 16 hours in the 
developing buffer, 50 mM Tris–HCl, pH 7.6, containing 5 mM CaCl2, 1 ?M ZnCl2, 1% 
Triton X-100 and 0.02% NaNO3. The gels were then stained with Coomassie Brilliant Blue 
for 2 h and destained with a solution containing 10% methanol and 10% acetic acid.  
10 Immunoblotting,?immunoprecipitation,?and?mass?spectrometry?
analyses?(I,??II,?III)?
Cell lysates were prepared using RIPA lysis buffer (50 mM Tris-HCl buffer, pH 7.4, 150 mM 
NaCl, 1% NP-40, 0.5% NaDOC, 0.1% SDS, and 0.02% (w/v) sodium azide, complete 
protease inhibitor cocktail (Roche), and 10 ?M of GM6001) and insoluble materials were 
removed by centrifugation. For immunoprecipitation, two times volume of Triton lysis buffer 
(50 mM Tris-HCl buffer, pH 8.0, containing 150 mM NaCl, 1% (v/v) Triton X-100, 0.02% 
(w/v) sodium azide, complete protease inhibitor cocktail, and 10 ?M GM6001) was added to 
each soluble cell lysate, followed by incubation with antibody conjugated agarose beads. 
After washes with the Triton lysis buffer, the protein complexes were eluted with Laemmli 
SDS-PAGE sample buffer. The soluble cell lysates and immunoprecipitated proteins were 
resolved by SDS–PAGE with a linear 4–20% gradient gel under reducing conditions 
followed by immunoblotting. For mass spectrometry analysis, immunoprecipitated proteins 
were subjected to SDS–PAGE followed by silver staining using Proteosilver Plus Stain Kit 
(Sigma).  The  aimed bands  were  cut  out  from the  silver  stained  gels  and  subjected  to  mass  
spectrometry analysis (LC-MS/MS) after trypsin digestion.  
11 Cell?surface?biotinylation?
Cells were rinsed at 4°C with ice-cold PBS and incubated in PBS containing 0.5 mg/ml of 
Sulfo-NHS-biotin (Thermo Fisher Scientific) on ice for 1 h. The reaction was terminated by 
washing with 10 mM Tris-HCl buffer, pH 7.4, containing 150 mM glycine for 10 min. The 
soluble cell lysates were subjected to immunoprecipitation and the immune complexes were 
detected with horseradish peroxidase–conjugated streptavidin (Dako). 
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12 Immunofluorescence?(I,?II,?III)?
Cells grown on collagen coated glass coverslips were washed with PBS and fixed with 4% 
PFA. After washing with Dulbecco’s PBS, the cells were incubated in Dulbecco’s PBS 
containing  5%  BSA  and  then  incubated  with  the  primary  antibody  for  1  h.  The  bound  
antibodies were detected using Alexa Fluor–conjugated secondary antibodies (Invitrogen). 
The coverslips were mounted on glass slides using Vectashield anti-fading reagent (Vector 
Laboratories). The cells were photographed by confocal imaging using LSM 5 DUO or LSM 
780 confocal microscopes (Carl Zeiss).  
13 3D?type???collagen?invasion?and?invasive?growth?analyses?(I,?II,?III)?
Rat tail type I collagen (Sigma) was dissolved in 0.2% acetic acid and neutralized with NaOH 
and diluted to a final concentration of 2.2 mg/ml in MEM. The collagen solution was cast 150 
?l into the upper chamber of Falcon cell culture inserts in 24-well cell culture plates and 
allowed to form a gel at 37°C for 1 hour. Tumour cells (3x105/ insert) in completed culture 
media were added on top of the gel. The medium was supplemented with recombinant human 
HGF and FGF2 as chemoattractants to the lower chamber. The cells were cultured at 37°C 
for 5 days replacing them with complete medium every second/third day. The gels were then 
fixed in 4% PFA, dehydrated and embedded into paraffin. Invading cells were counted and 
photographed from hematoxylin and eosin (H&E) stained paraffin sections using a Leica DM 
LB microscope and Image J software. 
Single cell suspension (3 x 103 cells/gel) was prepared in collagen I solution and formed 
collagen gel drops in 24-well cell culture plates. The gels were cultured for 4-6 days in 
completed culture media. The colonies were stained after 4% PFA fixation with TRITC-
conjugated phalloidin (Sigma) or indirect immunofluorescence staining and photographed 
using an LSM 5 DUO confocal microscope (Carl Zeiss).  
14 Mouse?tumour?growth?analysis?(II,?III)?
Cells were lentivirally transduced with a Renilla luciferase–GFP fusion reporter protein. The 
cells (2 × 106 cells/mouse) were implanted orthotopically into the abdominal subcutis of 
Severe combined immunodeficient (SCID) mice (5–7 weeks of age; Taconic) and allowed to 
grow for 4 to 8 weeks. Tumour growth was measured by a calliper, and metastasis to local 
lymph nodes were followed by non-invasive bioluminescence measurement after i.p. 
injection of coelenterazine (35 ?g in 100 ?L PBS; Synchem) using a Xenogen IVIS System.  
15 Histologic?analyses?and?immunohistochemistry?(II,?III)?
Mouse tumours and lymph nodes were collected and fixed with 4% paraformaldehyde, 
dehydrated, and embedded in paraffin followed by H&E, Herovici, and 
immunohistochemistry staining. The tissue sections were de-paraffinized in TissueClear 
(Tissue-Tek) and re-hydrated in graded ethanol series. After antigen retrieval by boiling in 
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sodium citrate buffer (10 mM Na citrate, 0.05% Tween-20, pH 6), the sections were 
incubated for 10 min in 0.6% (v/v) hydrogen peroxide. They were subsequently rinsed and 
incubated with 2.5% Normal Horse Serum (Vector Laboratories) for 30 min. Primary 
antibodies were incubated for 2 hours in blocking buffer, followed by incubation with 
peroxidase conjugated anti-mouse Ig/anti-rabbit Ig for 30 min. Detection was performed 
using Vectastain ABC kit according to manufacturer’s instructions. After washes slides were 
dehydrated and mounted using Cytoseal mounting medium (Electron Microscopy Sciences). 
The mouse tissues were also subjected to frozen sectioning (20 ?m) followed by 
immunoflorescence staining. Vessels with intravasated tumor cells were counted from H&E-
stained sections. 
Frozen or paraffin embedded human multiple human tumour and normal tissue arrays 
(FMC401, BRF401, and BRM961; US Biomax, Inc.) were subjected to 
immunohistochemistry with pre-titrated dilutions of antibodies.  
16 FGFR4?allele?genotyping?analysis?(I,?II)?
The fragments of FGFR4 cDNA containing the G388R site (1,329–1,331 bp) were amplified 
by PCR (primers: TACCAGTCTGCCTGGCTC and AGTACGTGCAGAGGCCTT) and 
digested with BstN1 (New England Biolabs). R388 allele was identified by a specific 126-bp 
fragment, and G388 allele by two fragments (97 and 29 bp). Unclear results were confirmed 
by sequencing. 
17 Rho-GTPase?activity?assay?(III)?
Soluble cell lysates were incubated with Rhotekin RBD-GST (for the RhoA activity assay) or 
PAK-1 PDB-conjugated agarose beads (for Rac1 and CDC42 activity assay) for 4 h at 4°C. 
The resulting bound Rho–GTPase complexes were analyzed by immunoblotting. Total RhoA, 
Rac1, and Cdc42 were detected from soluble cell lysates.  
18 Cell?detachment?and?cell-cell?repulsion?analysis?(III)?
Time-lapse microscopy imaging was performed on an Intelligent Imaging Innovations (3i) - 
Stallion HIS (Zeiss) microscope with a Zeiss AxioCam MRm camera and SlideBook 4.1 
software. The cells were seeded on chambers (BD) coated with monomeric collagen I 
(1.0×105 cells/cm2). An image was taken every 5 min at 37 °C with 5% CO2 for up to 5 or 12 
h. All movies were compiled and cell tracking was done using ImageJ MTrackJ and Manual 
Tracking Plug-In. The cell detachment or attachment responses were determined by counting 
the number of detaching or attaching cells followed for 90 min after cell collision. 
Quantification of cell repulsion was carried out as previously described (Paddock and Dunn, 
1986). In brief, the displacements 35 minutes before collision (A) and for 35 min following 
collision (B) were measured. The contact acceleration index (Cx) of vector B–A represents 
the difference between how far the cell has progressed in the direction of A and how far it 
would  have  gone  had  there  been  no  collision.  The  velocity  of  each  cell  was  determined  by  
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tracking the position of the nucleus in the first and last images divided by the total time and 
represented in a compass graph using MathLab software. 
19 Statistical?analysis?(I,?II,?III)?
All numerical values represent mean +/- SEM. Statistical significance was determined using 
two-tail Student´s t-tests or Mann–Whitney U test.  
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RESULTS?AND?DISCUSSION?
1 Identification?of?receptor?tyrosine?kinases,?FGFR4?and?EphA2,?as?
unique?regulators?of?proinvasive?MT1-MMP?activity?(I,?II,?III)??
Many types of tumour cells up-regulate MT1-MMP and use its proteolytic activities for their 
invasion. MT1-MMP proteolytic activities are regulated at the transcriptional or the 
posttranscriptional levels by several growth factor/cytokine-induced signalling and through 
interaction with cell surface or intracellular signalling molecules. However, cancer-associated 
molecular mechanisms of pro-invasive MT1-MMP activities have not been fully defined.  
To identify the upstream and co-operative protein kinase signalling for pro-invasive MT1-
MMP activity in cancer cells, we set up a systematic genome-wide gain-of-function human 
kinome screen. Individual 564 cDNAs constituting ~93% of all human protein kinases 
(Varjosalo et al., 2008) were expressed in human HT-1080 fibrosarcoma cells. The levels of 
proMMP2 activation were quantified as an indirect indication for MT1-MMP activities. From 
the  primary  screen,  we  chose  the  top  32  kinases  for  second  screen  (Fig.  1A  inI).  Among  
them, 21 kinases increased MMP-2 activation more than 2-fold relative to the mock-
transfected control (Fig. 1D in I). These kinases contained both novel and known MT1-MMP 
positive regulators. The latter group included downstream signalling molecules of IL-1and 
TNF-? signalling  as  well  as  receptors  of  TGF-? signalling (Fig. 1D in I). These signalling 
pathways are associated with MT1-MMP transcription (Lohi et al., 1996; Munshi et al., 2004; 
Rajavashisth et al., 1999), which thus validated the kinome screen. The novel MT1-MMP 
positive regulators involved two RTKs, FGFR4-R388 variant and EphA2. This library also 
contained  other  three  FGFR  family  members  (FGFR1,  FGFR2,  and  FGFR3)  and  ten  Eph  
receptors (EphA1, EphA3, EphA4, EphA5, EphA7, EphB1, EphB2, EphB3, EphB4, and 
EphB6). However, none of these kinases individually increased efficiently MT1-MMP-
mediated MMP2 activation over 2-fold (Fig. S1C in I, Fig.1A in III).  We continued to study 
the cooperative molecular mechanisms of pro-invasive MT1-MMP and FGFR4-R388 or 
EphA2 in cancer cell invasion, since the cell surface receptor kinases can be potential 
therapeutic targets for patients with cancer. 
2 FGFR4?polymorphism?acts?as?an?activity?switch?of?MT1-MMP-
mediated?cancer?cell?invasion?(I,?II)??
Although MT1-MMP can modulate FGFR2 signalling through MT1-MMP-FGFR2-ADAM9 
interaction in mouse calvarial osteogenesis (Chan et al., 2012), cancer-associated molecular 
mechanisms that are linking FGFRs to pro-invasive MT1-MMP activities have not been 
Figure 19. Structure of the FGFR4 
variants. FGFR4-R388 SNP is 
associated with aggressive cancer 
progression and poor prognosis of 
patients with several types of cancer.  
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reported. The FGFR4-R388 polymorphism has Gly to Arg conversion in its transmembrane 
domain (Figure 19). This variant expression has been linked to aggressive cancer progression 
and poor prognosis of patients with several types of tumours (Bange et al., 2002; da Costa 
Andrade et al., 2007; Spinola et al., 2005; Streit et al., 2004). However, the underlying 
molecular mechanisms of increased cancer progression caused by the FGFR4-R388 risk 
variant expression have remained unclear. 
2.1 The?FGFR4-R388?risk?variant?increases?MT1-MMP?levels?by?reducing?
lysosomal?degradation?of?MT1-MMP?(I)?
Since MT1-MMP gene expression is frequently up-regulated in malignant conditions, we first 
examined the effect of the FGFR4-R388 risk variant on MT1-MMP transcript. The FGFR4-
R388 did not affect MT1-MMP mRNA expression in HT-1080 cells and human breast 
carcinoma MDA-MB-231 cells (Fig. S2A in I). This variant was thought to regulate MT1-
MMP activity at posttranscriptional levels. Cell surface MT1-MMP is regulated by 
endocytosis coupled with lysosomal degradation or recycling to the cell surface (Zucker et 
al., 2002). We tested whether the FGFR4-R388 risk variant inhibits MT1-MMP degradation. 
In MDA-MB-231 cells, lysosomal inhibitor Bafilomycin A markedly increased endogenous 
MT1-MMP, while a proteasome inhibitor MG134 did not affect MT1-MMP levels (Fig. 2A 
in I). Consistent with an increased MT1-MMP activity, the FGFR4-R388 variant increased 
MT1-MMP protein level. In this variant expressing cells, the effect of Bafilomycin A was 
minor on MT1-MMP level (Fig. 2A-C in I). Therefore, lysosomal degradation of MT1-MMP 
is inhibited in the FGFR4-R388 risk variant expressing cells. In contrast, the FGFR4-G388 
variant expression decreased MT1-MMP levels (Fig. 2C and D in I). Importantly, this variant 
was up-regulated by inhibition of MT1-MMP activity and down-regulated by the increased 
MT1-MMP  after  Bafilomycin  A  treatment  (Fig.  2C  in  I).  Although  MT1-MMP  was  co-
precipitated  with  these  two  FGFR4  variants  as  well  as  their  corresponding  kinase  activity-
deficient (KD) proteins (Fig. 2D, S3A-B in I), the catalytically active FGFR4-R388 and 
FGFR4-G388 variants showed different effects on MT1-MMP protein stability.  
2.2 The?FGFR4-R388?risk?variants?increases?MT1-MMP?phosphorylation?
and?endosomal?stabilization?(I)?
We next studied how the FGFR4 variants regulate MT1-MMP stability. In stable FGFR4-
R388-expressing MDA-MB-231 cells, ectopic FGF2 treatment increased the phosphorylation 
levels of both FGFR4 and MT1-MMP, interaction of these proteins, and accumulation in the 
same endosomal compartments (Fig. 3A-D in I). In contrast, the co-localization of MT1-
MMP and the FGFR4-G388 or the KD proteins was poor and activated low risk variant did 
not increase MT1-MMP phosphorylation (Fig. 3A-C and S6 in I). Phosphorylation of a single 
tyrosine residue in the cytoplasmic tail of MT1-MMP by non-receptor tyrosine kinase Src 
regulates MT1-MMP endocytosis, which is also associated with tumour growth and invasion 
(Moss et al., 2009; Nyalendo et al., 2007; Nyalendo et al., 2008). Interestingly, MT1-MMP 
phohsphorylation by the FGFR4-R388 variant was inhibited by Src inhibitor, PP2 (Fig. S4D 
in I). Src is a downstream mediator of FGF signalling. The FGFR4-R388 risk variant-induced 
signalling thus can increase MT1-MMP phosphorylation and stability of both FGFR4-R388 
and MT1-MMP in the same endosomal vesicles through intracellular Src activity.  
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We further examined the stability of the FGFR4 variants themselves after ligand stimulation. 
The FGFR4-R388 risk variant was more stable compared to the FGFR4-G388 low risk 
variant after FGF2 treatment (Fig. 3E in I). The FGFR4-G388 variant was degraded rapidly 
after ligand-induced activation, which could be involved in MT1-MMP proteolytic activity 
since a synthetic broad-spectrum MMP inhibitor GM 6001 treatment sustained the expression 
levels  of  this  low risk  variant  (Fig.  3E in  I).  Correlated  with  the  stability  of  these  variants,  
MT1-MMP levels were increased after ligand stimulation only in the FGFR4-R388 variant 
expressing cells (Fig. 3E in I). The increased stability of the FGFR4-R388 variant rather than 
the physical interactions of FGFR-MT1-MMP can thus enhance the stabilization of the 
phosphorylated and endocytosed MT1-MMP. The increased stability of the activated FGFR4-
R388 sustains its autophosphorylation (Wang et al., 2008). Furthermore, an analogous of 
achondroplasia-causing mutation in FGFR3 transmembrane domain (FGFR3-G380R) leads 
to increased kinase activity and stability of the receptor recycling and decreased targeting of 
receptors to lysosomes (Cho et al., 2004; Eswarakumar et al., 2005). Therefore, the FGFR4-
R388 can alter the interactions of the activated receptor with vesicular sorting proteins for 
recycling instead of lysosomal degradation similarly to FGFR3 (Cho et al., 2004). MT1-
MMP can be also sorted to the recycling pathways after endocytosis together with the 
FGFR4-R388 variant, where the activated FGFR4-R388 signalling increases MT1-MMP 
phosphorylation by Src. In contrast, the unstable FGFR4-G388-MT1-MMP complexe is 
rapidly degraded after endocytosis. In this complex, proteolytic activity of MT1-MMP can be 
involved in this process. 
2.3 MT1-MMP?and?FGFR4-R388?activate?and?MT1-MMP?and?FGFR4-G388?
suppress?each?other?(I)?
To study the impact of MT1-MMP phosphorylation on the interaction of the FGFR4 and 
MT1-MMP, we constructed the MT1-Y573F mutant in which the tyrosine residue in 
cytoplasmic domain was changed to phenylalanine. This mutant did not alter MT1-MMP-
mediated MMP2 activation (Fig. S7B in I). In the endogenous FGFR4-R388 variant 
expressing MDA-MB-453 breast carcinoma cells, the wild-type MT1-MMP was co-localized 
with the FGFR4-R388 at cell junctions and intracellular vesicles (Fig, 4A in I). Consistent 
with the previous report (Moss et al., 2009), the MT1-Y/F mutant was accumulated on the 
cell surface. In this mutant expressing cells the FGFR4-R388 localization was mainly 
detected in the intracellular vesicles (Fig. 4A in I). Furthermore, MT1-Y/F led to cell 
junctional disassembly and elongated cell morphology (Fig. 4A in I). Consistently, 
immunoblotting analysis showed that the interaction of FGFR4-R388 with MT1-Y/F was 
weaker than with MT1-MMP (Fig. 4C in I). Of note, this FGFR4-R388-MT1-MMP 
interaction enhanced the phosphorylation of both MT1-MMP and the FGFR4-R388 variant 
(Fig. 3A-C and 4C in I). On the other hand, in FGFR4-G388 stably expressing MDA-MB-
231 cells MT1-MMP and FGFR4-G388 were expressed in different intracellular vesicles 
(Fig. 4B in I). The expression of MT1-Y/F dramatically decreased FGFR4-G388 expression 
in the same cells (Fig. 4B in I).  
On the cell surface, FGFR4 cooperates with cell-adhesion receptors, such as N-cadherin and 
NCAM to regulate cell-cell and cell-matrix adhesion (Cavallaro et al., 2001; Francavilla et 
al., 2007; Lehembre et al., 2008; Nakamura et al., 2008). The cancer cells used in this study, 
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MDA-MB-453 cells express negligible levels of cadherins, such as E-Cadherin, N-Cadherin, 
Cadherin-11, and P-cadherin (Nieman et al., 1999), however, they instead express other cell-
surface adhesion proteins, e.g. epithelial cell adhesion molecule (EpCAM), and MDA-MB-
231 cells express cadherin-11 (Nieman et al., 1999; Osta et al., 2004; Prang et al., 2005). At 
cell junctions, endogenous FGFR4-R388 may cooperate with these cell surface molecules to 
maintain cell–cell adhesion. Loss of FGFR4-R388 from the cell surface and cell–cell 
junctions in MT-Y/F expressing cells can thus lead to cell-junctional disassembly and 
induction of EMT-like cell phenotype transition. In parallel, accumulation of MT1-Y/F on the 
cell surface facilitates the FGFR4-G388 variant degradation. Therefore, MT1-Y/F can escape 
from downregulation by the FGFR4-G388 variant and sustain its proteolytic activities. 
2.4 The?FGFR4-G388R?risk?variant?promotes?MT1-MMP-mediated?collagen?
degradation?(I,?II)?
Since MT1-MMP is essential for collagen degradation (Hotary et al., 2000), we examined the 
effect of the FGFR4 variants on MT1-MMP proteolytic activities in 3D collagen invasion 
assay. The cross-linked collagen I matrix typifies the ECM of collagen-rich stroma (Egeblad 
et al., 2010; Sabeh et al., 2009). The cells were seeded atop 3D collagen and allowed to 
invade for 5 days. FGFR4-R388 significantly increased MDA-MB-231 cell invasion, whereas 
the FGFR4-G388 and their KD proteins did not affect MT1-MMP-mediate collagen 
degradation (Fig. 5A, B and S9 in I). We further used human prostate carcinoma cell lines for 
testing the functional relevance of the endogenous MT1-MMP and the FGFR4-R388 or the 
FGFR4-G388 variant. PC3 prostate carcinoma cells express both MT1-MMP and the 
FGFR4-R388 risk variant, and DU145 cells express MT1-MMP and the FGFR4-G388 low 
risk variant. PC3 cells invaded into collagen gels efficiently, which was inhibited by the 
FGFR4-R388 variant knockdown (Fig. 3 in II). On the other hand, DU145 displayed low 
level invasiveness (Fig. 3 in II). As expected, invasion of all these cells was enhanced by 
MT1-MMP over-expression and strongly impaired after MT1-MMP knockdown (Fig. 5A, B 
and S9 in I and Fig. S4D in II). Thus, the FGFR4-R388 variant and MT1-MMP cooperatively 
promote breast and prostate carcinoma cell invasion into 3D collagen matrices. Consistent 
with increased cancer cell invasion, on the thin layers of gelatin or cross-linked collagen, or 
within 3D collagen matrices the FGFR4-R388 specifically increased MT1-MMP levels at the 
leading edges of invading cells (Fig. 5C and D in I).  
Rapid endocytosis of MT1-MMP and its accumulation at the invasive front can promote 
cancer cell invasion efficiently (Bravo-Cordero et al., 2007; Poincloux et al., 2009; Remacle 
et al., 2003; Uekita et al., 2001). By increasing MT1-MMP in invasive protrusions, the 
FGFR4-R388 risk variant co-operatively enhances pericellular ECM degradation and further 
promotes cancer cell invasion. Taken these results, we proposed a schematic model of the 
function of FGFR4-MT1-MMP complexes shown in Fig. 4D in I. The both FGFR4 variants 
form complex with MT1-MMP, however, the different stability of each variant increases or 
decreases MT1-MMP levels and activities. The FGFR4-R388 risk variant forms a complex 
with MT1-MMP on the cell membranes, where this variant can phosphorylate MT1-MMP in 
its cytoplasmic tail via Src activity. The internalized the FGFR4-R388-MT1-MMP 
complexes can be selectively sorted into recycling endosomes, which may reflect higher 
stability of both proteins and increase the accumulation of MT1-MMP and the FGFR4-R388 
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at the leading edge of invading cells. In this complex, MT1-MMP also increases 
phosphorylation levels of this risk variant. Thus, the FGFR4-R388-MT1-MMP axis can 
enhance MT1-MMP proteolytic activity and prolong FGF signalling, resulting in aggressive 
breast and prostate carcinoma cell invasion. In contrast, the complexes with the unstable 
FGFR4-G388 variant are mainly delivered to lysosomes and rapidly degraded. The cell-
surface accumulated MT1-MMP can also degrade the FGFR4-G388 variant and cell surface 
adhesion molecules, leading to cell junctional dissociation and induction of more motile-type 
elongated cell morphology. 
3 FGFR4?and?MT1-MMP?are?co-expressed?at?invasive?edge?in?human?
tumours?(II).?
FGFR4 is frequently overexpressed in human epithelial carcinomas, such as breast, prostate 
and hepatocellular carcinomas (Ho et al., 2009; Jaakkola et al., 1993; Sahadevan et al., 2007). 
The overexpressed FGFR4 contributes to cancer progression and poor prognosis (Ho et al., 
2009; Sahadevan et al., 2007). In breast tumours, the overexpression of FGFR4 can also be 
often linked to anti-cancer drug resistance (Meijer et al., 2008). We studied the FGFR4-MT1-
MMP axis in human tumour progression using human carcinoma biopsies and Gene Sapience 
database. 
3.1 The?FGFR4-R388?variant?associates?with?MT1-MMP?mRNA?expression?
in?high?grade?(Grade?3)?breast?carcinomas?(II)?
To study whether the FGFR4 variants and MT1-MMP are co-expressed in human tumours, 
we used a qPCR array from 48 human breast cancer biopsies. Consistent with the previous 
report (Bange et al., 2002), 56% of samples had homozygous or heterozygous FGFR4-R388 
risk variant expression (R/R, 8%; G/R, 48%) and 44% of samples had homozygous FGFR4-
G388 low risk variant expression (G/G; Fig. 1A in II). All homozygous FGFR4-R388 
samples were detected from the highest-grade tumours coupled with low level of FGFR4 and 
increased MT1-MMP mRNA expression, which can be consistent with the poor prognosis 
reported for patients with this allele (Bange et al., 2002; da Costa Andrade et al., 2007; 
Spinola et al., 2005; Streit et al., 2004). No significant correlation was observed between  the 
expression levels of FGFR4 and MT1-MMP mRNAs in individual breast tissue biopsies (Fig. 
1A in II), suggesting that the FGFR4-R388 variant may indirectly contribute to MT1-MMP 
transcription in the carcinoma cells and/or stroma in vivo within high grade human breast 
tumours.   
3.2 MT1-MMP?and?FGFR4?are?co-expressed?in?stroma/tumour?border?and?
in?invasive?front?of?breast,?lung,?colon,?and?prostate?carcinomas?(II)??
To analyse the expression of both FGFR4 and MT1-MMP in different stage of human breast 
tumours, we assessed the expression and localization of these proteins in 42 normal or 
malignant breast tissue samples by immunohistochemistry. FGFR4 was faintly stained in 
luminal epithelium in normal breast tissues, whereas MT1-MMP was undetectable (Fig. 1C 
in II; modestly positive stroma in 2/4). Consistent with the previous reports (Okada et al., 
1995; Szabova et al., 2005; Thussbas et al., 2006), FGFR4 was strongly detected in 
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carcinoma cells (20/38) and MT1-MMP was detected in reactive stroma (carcinoma in situ 
2/8; invasive ductal carcinoma, 17/28; invasive lobular carcinoma, 2/2), in myoepithelium in 
breast carcinoma in situ (7/8), and in poorly differentiated carcinoma cells of invasive ductal 
carcinomas (13/28; Fig. 1C and D in II). Importantly, both FGFR4 and MT1-MMP were 
expressed in the latter two types of cells in breast carcinomas (Fig. 1C and D in II). We 
further assessed the co-expression of FGFR4 and MT1-MMP in many types of human 
tumours using 14 different normal and malignant human tissue samples. MT1-MMP was up-
regulated in tumour cells (9/14) and/or reactive stroma (9/14), whereas FGFR4 expression 
was mainly detected in the tumour cells (5/14; Table S1 in II). Particularly, co-localization of 
MT1-MMP and FGFR4 proteins were detected in the leading edge of collectively invading 
lung squamous cell carcinomas and colon adenocarcinomas (Fig. 2A in II). Thus, the co-
expression of these proteins is restricted to the tumour/stroma border and the invasive front of 
many types of carcinomas, as well as to highly invasive undifferentiated breast carcinoma 
cells. 
GeneSapiens database analysis (Kilpinen et al., 2008) revealed that similar to the breast tissue  
biopsies, in overall expression of FGFR4 and MT1-MMP expression  was  low  or  not  
correlated to each other in individual tissue biopsies from different human tumour types, even 
though  FGFR4 and MT1-MMP were frequently up-regulated in same tumour types (Fig. 1A 
and 2B in II). Previously we revealed that the FGFR4 variants regulate MT1-MMP activities 
at posttranscriptional levels (I). This may explain the low correlation of FGFR4 and MT1-
MMP mRNA expression  in  many types  of  carcinomas.  However,  there  was  one  interesting  
exception; a positive correlation in prostate cancer. Therefore, in prostate carcinomas there is 
a possibility of FGFR4-MT1-MMP interplay that may contribute to cancer progression. 
4 FGFR4?regulates?MT1-MMP–dependent?ECM?degradation?and?
tumour?progression?in?3D?collagen?matrix?and?in?vivo?(II)?
Since the expression of endogenous FGFR4 and MT1-MMP are positively correlated in 
individual  prostate  carcinomas,  we  used  prostate  carcinoma  cell  lines  to  study  how  the  
FGFR4-MT1-MMP axis regulates tumour growth and invasion in 3D collagen matrices and 
mouse xenograft model. PC3 and DU145 human prostate carcinoma cell lines express both 
MT1-MMP and homozygous FGFR4-R388 risk variant or the FGFR4-G388 low risk variant, 
respectively (Sahadevan et al., 2007). The expression of FGFR4 and MT1-MMP was stably 
silenced by lentiviral shRNAs. 
4.1 FGFR4-R388?and?MT1-MMP?induce?epithelial-to-mesenchymal?
transition?(EMT)?(II)?
In addition to invasion, MT1-MMP proteolytic activity enhances invasive cell growth within 
collagen matrices (Hotary et al., 2003). PC3 (R/R) and DU145 (G/G) cells after MT1-MMP 
or FGFR4 knockdown were implanted within three-dimensional cross-linked collagen I 
matrices as single cell suspension. The cells were allowed to grow for 6 days. Both PC3 and 
DU145 cells formed sphere-shaped colonies (Fig. 4A in II). Consistent with invasion abilities 
from atop collagen (Fig. 3 in II), PC3 colonies displayed more invasive protrusions and 
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invading individual cells, which were abolished by either the FGFR4-R388 or MT1-MMP 
knockdown (Fig. 4A in II). Consistent to our previous results with breast carcinoma cells (I), 
the FGFR4-R388 variant depletion in PC3 prostate carcinoma cells also decreased MT1-
MMP protein levels and further increased the epithelial organization in the PC3 cells 
observed by increased cortical actin structure (Fig. 4A-C in II). In parallel, either the FGFR4-
R388 or MT1-MMP knockdown increased E-cadherin levels coupled with suppression of 
cadherin-11 and N-cadherin expression (Fig. 4D in II). The FGFR4-R388 knockdown also 
reduced pro-migratory FRS2 and Src signalling, but not mitogenic signalling and cell 
proliferation in 2D culture (Fig. 4D and S5B-D in II). Since the expression balance between 
E-cadherin and N-cadherin or cadherin-11 is linked to EMT and the expression of N-cadherin 
and cadherin-11 can promote prostate cancer metastasis (Chu et al., 2008), the FGFR4-R388 
variant expression can be involved in the induction of EMT and aggressive prostate cancer 
progression.  
On the other hand, the FGFR4-G388 variant knockdown in DU145 cells up-regulated MT1-
MMP protein levels and increased collective invasion within 3D collagen matrix (Fig. 4A, B, 
and S5A in II). MT1-MMP knockdown in turn increased the FGFR4-G388 transcription (Fig. 
4B and C in II). This suggests that there is a negative reciprocal regulation between MT1-
MMP and the FGFR4-G388 variant in cancer cell invasion. FGFR4-G388 downregulates 
MT1-MMP protein levels and MT1-MMP knockdown increases its negative regulator, 
FGFR4-G388 level. This FGFR4-G388-MT1-MMP axis can thus suppress DU145 cell 
invasion within 3D collagen matrices. The expression of the FGFR4-G388 variant did not 
affect cadherin expression, pro-migratory signalling, or cell growth (Fig. 4Dand S5B-D in II). 
4.2 Endogenous?FGFR4/MT1-MMP?axis?controls?prostate?carcinoma?cell?
differentiation,?extracellular?matrix?degradation,?and?EMT?in?vivo?(II)?
To investigate the effects of the FGFR4-MT1-MMP axis on tumourigenesis in vivo, tumour 
growth, invasion, and collagen content were analysed after subcutaneously injection of PC3 
and DU145 cells into SCID mice. The xenografts were allowed to grow for 6-8 weeks. The 
growth rates of PC3 tumours were dramatically decreased after stable knockdown of either 
MT1-MMP or the FGFR4-R388 risk variant (Fig. 5A in II). Mitotic index was decreased 
accordingly and PC3 cell invasion into vascular and lymph node capillaries was also 
impaired, while tumour collagen content was increased in these tumours (Fig. 5B and C, S6B, 
S7, and Table S3 in II). Consistent with in vitro study, FGFR4-R388 knockdown decreased 
MT1-MMP protein levels in mouse tumours as compared to control tumours (Fig. 6A in II). 
Since MT1-MMP is a major collagenase in vivo and its ECM remodelling activities promote 
cancer cell growth and invasion (Holmbeck et al., 1999; Hotary et al., 2003; Rowe and 
Weiss, 2008; Sabeh et al., 2009), the reduced MT1-MMP levels correlated with increased 
accumulation of collagen matrix within and around tumours as well as with impaired tumour 
growth and vascular and lymph node invasion in both MT1-MMP and the FGFR4-R388 
variant depleted PC3 tumours. In contrast, the FGFR4-G388 low risk variant knockdown 
resulted in increased DU145 tumour growth and vascular invasion (Fig.5 in II). This could be 
occurred by MT1-MMP upregulation, since the FGFR4-G388 variant depletion increased 
MT1-MMP protein levels in vitro and the increased MT1-MMP protein content was detected 
in particularly at the tumour edges (Fig 5 and 6A in II). Consistently, intratumoural collagen 
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and fibrous capsule around the tumours were decreased in the FGFR4-G388 depleted DU145 
tumours (Fig. 5C in II). Thus, the FGFR4-G388 knockdown triggers MT1-MMP induction at 
the tumour edges, which could promote invasion of cancer cells that carry this low risk 
variant in vivo and within 3D collagen matrix. 
Of note, the impaired growth and invasion of MT1-MMP and the FGFR4-R388 knockdown 
tumours were coupled with increased epithelial polarization and some acinar lumen 
formation (Fig. 6B in II). Furthermore, the basement membrane component, collagen IV was 
accumulated around the tumour cells, and cadherins were translocated to cell-cell junctions in 
these knockdown tumours (Fig. 6B in II). In contrast, the FGFR4-G388 silencing did not 
result in collagen IV accumulation in the DU145 tumours (Fig. S8D in II). Since mRNA 
levels  of  collagens  (collagen  IA,  IIA,  and  IV)  were  not  altered  by  MT1-MMP  or  FGFR4-
R388 expression levels, the FGFR4-R388-MT1-MMP axis enhances the degradation of both 
basement membrane and fibrillar collagen components in the invasive PC3 tumours. 
Increased MT1-MMP on the cell surface can directly contribute to the induction of EMT by 
cleaving E-cadherin and other cell surface adaptor proteins (Ghajar and Bissell, 2008). Taken 
together, we demonstrated that the FGFR4 polymorphism can act as an activity switch of the 
FGFR4 and MT1-MMP complex in vitro and in vivo. At the stroma/tumour border or in the 
tumour invasive front the FGFR4-R388-MT1-MMP axis increases MT1-MMP proteolytic 
activities and FGFR4-FRS2-Src pro-migratory signalling, resulting in induction of EMT and 
promoting prostate tumour growth and invasion into adjacent interstitial tissues as well as 
into vessels by basement membrane and interstitial matrix degradation. The FGFR4-G388 
low risk variant instead suppresses MT1-MMP levels at posttranscriptional levels and thus 
decreases prostate and breast carcinoma cell invasion. MT1-MMP in turn down-regulates this 
variant transcriptionally.  
5 EphA2?cleavage?by?MT1-MMP?triggers?single?cancer?cell?invasion?
via?homotypic?cell?repulsion?(III)?
EphA2 signalling regulates cell-cell and cell-matrix communications and cellular polarity and 
thus assists in maintaining normal tissue homeostasis (Miao and Wang, 2012). Aberrant 
expression or activation of EphA2 signalling can affect cancer cell-cell interactions and 
cancer cell motility through Rho-GTPase-mediated actomyosin contractility. EphA2 
overexpression has been linked to aggressive progression of many types of cancer (Brantley-
Sieders, 2012; Margaryan et al., 2009; Wykosky and Debinski, 2008). In glioblastoma and 
breast carcinomas, EphA2 overexpression is often coupled with low ephrinA1 expression 
(Macrae et al., 2005; Wykosky et al., 2005). However, the underlying cell-surface 
interactions and molecular mechanisms of EphA2-mediated cancer cell invasion have 
remained unclear.  
5.1 EphA2?and?MT1-MMP?are?co-expressed?in?invasive?breast?carcinoma?
cells?(III)?
From the kinome screen, we identified EphA2 as a positive regulator for pro-invasive MT1-
MMP in HT-1080 human fibrosarcoma cells. To study the potential relevance of such 
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regulation in cancer cell invasion, we first assessed the expression of EphA2 and MT1-MMP 
in non-invasive (ZR-75-1, MCF-7, BT-474, T47D, and MDA-MB-453; Neve et al., 2006) 
and invasive (SUM159, Hs578T, BT-549, and MDA-MB-231; Neve et al., 2006) breast 
carcinoma cell lines. Among them, EphA2 and MT1-MMP were selectively co-expressed in 
invasive cell lines where the EphA2 cognate ligand, ephrinA1 expression was low (Fig. 1B, 
C and S1A in III). Accordingly, phosphorylation of EphA2 was relatively poor (Fig. 1B, C 
and S1A in III). In contrast, in non-invasive breast carcinoma cells the expression of EphA2 
and MT1-MMP was low coupled with expression of ephrinA1 (Fig. 1B, C and S1A in III; 
Neve et al., 2006).  
Since EphA2 and MT1-MMP are up-regulated in invasive breast carcinoma cells, the effects 
of EphA2 on cell invasion were tested by invasion and invasive growth assays in cross-linked 
3D collagen I matrix. Consistent with the expression of MT1-MMP, SUM159, Hs578T, BT-
549, and MDA-MB-231 cells invaded into collagen matrices from atop collagen, which was 
impaired by either EphA2 or MT1-MMP knockdown by lentiviral shRNAs (Fig. 1E-G in III). 
These cells also grew efficiently within 3D collagen matrix and displayed variety types of 
invasive colony phenotypes (Fig. 2A in III). SUM159 and Hs578T cells that invaded more 
efficiently with elongated morphologies than MDA-MB-231 and BT-549 cells formed 
multicellular  outgrowths  rich  in  actin  stress  fibers  (Fig.  1E,  2A-C  and  S1H  in  III).  On  the  
other hand, BT-549 cells grew in sphere-like colonies surrounded by rounded singly-invading 
cells with cortical actin. MDA-MB-231 cells had cortical actin coupled with more elongated 
morphology (Fig. 2A-C and S1H in III). EphA2 or MT1-MMP knockdown also reduced the 
invasive growth of these cells (Fig. 2D in III). Importantly, EphA2 depletion decreased MT1-
MMP transcription and protein levels (Fig. 1H and S1C in III). Furthermore, EphA2 and 
MT1-MMP knockdown did not affect cell growth in 2D culture (Fig. S1I and J in III), thus 
suggesting that EphA2 may cooperate with MT1-MMP to regulate different types of cancer 
cell invasion within collagen matrices. MT1-MMP activity is likely to be regulated by EphA2 
at transcriptional level.  
One of the EphA2 downstream signalling, Src activation was impaired by EphA2 knockdown 
in BT-549 and MDA-MB-231 cells (Fig. 1I in III). Furthermore, EphA2 knockdown also 
decreased activation of Src in BT-549 and MDA-MB-231 cells (Fig. 1I in III). Src can 
regulate overall cell motility (Huveneers and Danen, 2009), and be associated with MT1-
MMP activities (Barbolina et al., 2007; Nyalendo et al., 2007; Moss et al., 2009). Thus, Src 
activity can be involved in the potential cooperational regulation between EphA2 and MT1-
MMP in breast carcinoma cell invasion.  
5.2 MT1-MMP?cleaves?EphA2?to?modulate?receptor?localization?and?cell?
junctional?properties?(III)??
To test the potential interaction of EphA2 and MT1-MMP in the different invasive breast 
carcinoma cells, we assessed the subcellular localization of these proteins in 2D culture. On 
plastic surface, SUM159 and Hs578T cells displayed mesenchymal-type phenotype with 
prominent actin stress fibres, while BT-549 and MDA-MB-231 cells displayed more cortical 
actin and inter-cellular spaces (Fig. 3B in III). We also observed the dispersed localization of 
EphA2 in SUM159 and Hs578T cells, whereas EphA2 was distinctly distributed to 
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perinuclear compartments and cell surface in BT-549 and MDA-MB-231 cells (Fig. 2A, 3B 
and S1K in III). In MDA-MB-231 cells, EphA2 knockdown increased actin stress fibres (Fig. 
3C-E in III). MT1-MMP knockdown in turn reduced EphA2 accumulation in intracellular 
vesicles resulting in more dispersed localization and reduced inter-cellular spaces (Fig. 3C-E 
in III). Of note, either EphA2 or MT1-MMP knockdown did not alter EphA2 localization in 
SUM159 cells (Fig. S1J in III), although MT1-MMP was co-precipitated with EphA2 in 
SUM159, BT-549, and MDA-MB-231 cells (Fig. 3G in III). Similarly, Src inhibition 
stabilized EphA2 on the cell surface and dramatically reduced intracellular localization and 
cell-cell spaces (Fig. 3F in III). Therefore, MT1-MMP is associated with EphA2 intracellular 
localization and cell junctional properties through Src activation in some types of cells, such 
as MDA-MB-231 cells and BT-549 cells.  
Interestingly EphA2 was prominently processed only in BT-549 and MDA-MB-231 cells, 
resulting in the formation of ~60 and ~50 kD fragments (Fig. 3H in III). The appearance of 
these fragments was reduced after MT1-MMP knockdown in MDA-MB-231 cells (Fig. 3I in 
III). Thus, MT1-MMP constitutively cleaves EphA2 and generates the ~60 kD and the ~50 
kD fragments in these cells. The recombinant ephrinA1 treatment also increased ~50 kD 
fragment,  which was a major fragment detected in BT-549 cells (Fig.  3H and I  in III).  The 
tested invasive breast carcinoma cells displayed different invasive phenotypes and EphA2 
subcellular localization in 2D culture and within 3D collagen matrices. The physical EphA2-
MT1-MMP interaction and constitutive cleavage of EphA2 was found in cortical actin-rich 
less elongated MDA-MB-231 cells and rounded BT-549 cells. In these cells EphA2 
expression can also induce Src activation. Since low levels of ephrinA1 and other ligands are 
expressed in MDA-MB-231 and BT-549 cells (Macrae et al., 2005), upon cell-cell contact the 
expressing ligands in these cells can be sufficient to trigger limited receptor clustering and 
phosphorylation and further EphA2-dependent Src signalling activation. MT1-MMP may 
interact  with  EphA2 and  cleave  the  receptor  in  the  EphA2 clusters,  leading  to  Src  activity-
dependent intracellular translocation of EphA2 and cell junctional disassembly. BT-549 cells 
express  ephrin  ligands  at  higher  levels  as  compared  to  MDA-MB-231  cells  (Macrae  et  al.,  
2005), which may reflect higher levels of ~50 kD fragment and more rounded single-cell 
phenotype of BT-549 cells within 3D collagen matrix. The cleavage of EphA2 was negligible 
in the mesenchymal-type SUM159 and Hs578T cells, even though MT1-MMP was co-
precipitated with EphA2 in SUM159 cells. Therefore, the different types or magnitudes of 
receptor activation may be implicated in EphA2-MT1-MMP axis.  
5.3 MT1-MMP?cleaves?EphA2?at?fibronectin?type-III?domain?in?cis?on?the?
cell?surface?(III)?
To identify the cleavage sites of EphA2 by MT1-MMP, we performed mass-spectrometry 
(LC-MS/MS) analysis. The cleavage area was located in Fibronectin type-III domain 1 (FN1; 
Fig. 4D and E in III). MEROPS database analysis (http://merops.sanger.ac.uk/index.shtml) 
revealed that the identified cleavage area contained the consensus and plausible substrate 
sequences for MT1-MMP. Further analyses showed that EphA2 was processed by MT1-
MMP on the cell surface, when both proteins were expressed in the same cells (Fig. 4I and K 
in III). Previously it has been reported that upon binding of EphA receptor at cell-cell 
contacts, ephrinA was cleaved by adjacent cell surface ADAM proteases (Hattori et al., 2000; 
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directional switches upon collision, depending on MT1-MMP activity (Fig. 5D-F, S2D and E 
in III). Therefore, the EphA2 cleavage by MT1-MMP can promote contact-mediated 
repulsive cell movement upon EphA2 cleavage.  
5.5 Prominent?EphA2?cleavages?promote?RhoA?activation?and?single-cell?
invasion?within?3D?collagen?matrices?(III)?
Since the higher levels of constitutive EphA2 cleavage in BT-549 cells is appeared to be 
correlated with more single-cell invasion phenotype within 3D collagen matrices, we 
assessed if the cell repulsion triggered by EphA2 cleavage is linked to different types of 
cancer cell invasion. MDA-MB-231 cells expressing EphA2, EphA2-D/I, EphA2-G/R, and 
the kinase activity-deficient proteins (EphA2-KD and EphA2-KD-D/I) were implanted in 
cross-linked 3D collagen matrices as single cell suspension. Control and EphA2 expressing 
cells  formed  coherent  cell  colonies,  where  EphA2  was  detected  in  the  cell  surface  and  
intracellular compartments (Fig. 6A in III). The cleavage-prone EphA2-D/I expression 
resulted in single-cell invasion within 3D collagen, while the cleavage-resistant EphA2-G/R 
cells formed large collectively invading colonies (Fig. 6A-D in III). Consistent with 2D 
culture, EphA2-D/I was mainly detected in the intracellular vesicles and EphA2-G/R was 
dispersed in the cytoplasm (Fig. 6A in III). Increased EphA2 cleavage and intracellular 
localization increased RhoA activation and phosphorylation of myosin light chain (MLC) in 
both 2D and 3D culture (Fig. 6E and S3C in III). When the EphA2 kinase activity was 
impaired, the cells expressing EphA2-KD or EphA2-KD-D/I protein formed coherent 
colonies with multicellular sprouts with mesenchymal-type elongated cells, even though the 
EphA2-KD-D/I was efficiently cleaved in ~60 kD fragment (Fig. 6A-D and S3A in III). 
These KD proteins appeared to decrease the activation levels of RhoA (Fig. 6E in III), thus 
catalytically active EphA2 kinase activity is required for breast carcinoma cell transition to 
more rounded morphology. Since ligand-induced EphA2 signalling leads to cell rounding 
coupled with loosing cell-cell and cell-matrix interactions (Miao et al., 2000; Parri et al., 
2009; Taddei et al., 2011), upon cell collision EphA2-MT1-MMP-Src signalling can trigger 
cell body retraction and cell junctional dissociation via RhoA-mediated actomyosin 
contraction (Fig. 10 in III). Increased MT1-MMP expression by EphA2 may further promote 
effective EphA2-D/I expressing single-cell invasion within collagen. In 3D condition, cell 
junctional assembly, integrin-mediated cell-ECM adhesion, pericellular ECM degradation 
can  differently  regulate  cell  motility  and  cell  phenotype  from  2D  condition  (Friedl  and  
Alexander, 2011; Harunaga and Yamada, 2011; Sabeh et al., 2009). However, the MT1-
MMP-EphA2 axis regulates RhoA-mediated cell repulsive movement in both 2D and 3D 
cultures, thus suggesting that EphA2 cleavage and EphA2-MT1-MMP interaction can more 
uniformly function in cancer cell invasion on sheet-like BMs as well as within 3D interstitial 
tissues. Furthermore, EphA2 is cooperated with other RTK signalling to promote collective 
cell invasion in ligand-independent manner (Hiramoto-Yamaki et al., 2010; Miao and Wang, 
2009). The potential cross-talk between EphA2 and other RTK signalling can be thus one 
mechanism of mesenchymal-type cell invasion.  
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5.6 EphA2?cleavage?promotes?single?cell?dissemination?in?vivo?(III)??
To study if the EphA2-MT1-MMP axis regulates cancer invasion phenotype in vivo, control 
and EphA2 or EphA2-D/I stably-expressing MDA-MB-231 cells were othotopically injected 
into the mammary fat pad of SCID female mice. All xenografts formed tumours within 4 
weeks. The difference in the growth rate of each xenograft was minor, however each tumour 
showed different cancer cell phenotype. Control and EphA2 expressing cells grew 
cohesively, while the cells in EphA2-D/I tumours dissociated cell-cell junctions and invaded 
as single cells into stroma (Fig. 8A, B, E and S3G in III). In the metastatic lymph nodes, the 
control cells remained mainly within cortex with less MT1-MMP expression compared to the 
primary tumours (Fig. 8C, D, S3E and F; metastasis in sentinel lymph nodes; 2/5 in III). 
Since cancer cells switch their phenotypes from motile invasive to growth phenotype in the 
metastatic sites (Giampieri et al., 2009), the decreased MT1-MMP level in the lymph nodes 
of control tumour-bearing mice can be a sign of this transition. EphA2 expressing cells 
formed coherent metastatic colonies, the metastatic EphA2-D/I instead displayed poor cell-
cell contacts even more than in primary tumours (Fig. 8C-E and S3E-G; metastasis in sentinel 
lymph nodes; 2/5; metastasis in sentinel lymph nodes of EphA2-D/I expressing cells; 4/5 in 
III). Consistent with EphA2 effect on MT1-MMP transcript (Fig. 1H and S1C in III), EphA2 
increased MT1-MMP throughout the tumours (Fig. 8 and S3E-G in III). Importantly, the 
cleavage-prone EphA2-D/I increased MT1-MMP at higher levels as compared to EphA2 in 
vivo (Fig.  8  and  S3E-G in  III).  Although the  mechanism remains  to  be  elucidated,  cleaved  
intracellular active EphA2-induible signalling may directly or indirectly increase MT1-MMP 
levels, facilitating cancer invasion and cell phenotype switch from collective to single-cell 
mode in vivo.  
To further study the relevance of the EphA2-MT1-MMP axis in human breast carcinoma 
progression, expression and localization of EphA2 and MT1-MMP were assessed by 
immunohistochemistry using human tumour array containing invasive breast tumours with 
matched normal tumour-adjacent tissue or lymph node metastasis. EphA2 is typically 
expressed in tumour epithelium, while MT1-MMP expression is induced at invasive edge and 
reactive stroma (Brantley-Sieders et al., 2011; Okada et al., 1995; Sabeh et al., 2009; 
Sugiyama et al., 2010; Szabova et al., 2005). Consistently, EphA2 was detected in luminal 
epithelium and carcinoma cells and MT1-MMP was in both the carcinomas and reactive 
stroma (Fig. 9A, B and S4 in III). Expression of both EphA2 and MT1-MMP was high in 
invasive breast carcinomas as compared to tumour-adjacent normal tissues. Interestingly, the 
intracellular EphA2 co-localized with the up-regulated MT1-MMP in invasive edge and 
dissemination cancer cells within stroma of human breast carcinomas (Fig. 9A, B and S4 in 
III). Therefore, the EphA2 cleavage and EphA2-MT1-MMP interaction can function in 
context-dependent cancer cell–cell communications in vivo.   
 ?
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CONCLUSIONS?AND?PERSPECTIVES?
Cancer invasion promotes cancer cell dissemination from a locally growing tumour to regions 
throughout the body and thus becomes a major clinical  problem. In this thesis we aimed to 
identify novel protein kinases that regulate pro-invasive MT1-MMP activities in cancer cells. 
The FGFR4-R388 variant and EphA2 were identified as positive regulators that cooperate 
with MT1-MMP to regulate cancer progression and cancer invasion plasticity.  
FGFR4-R388 is a germline SNP variant of FGFR4. Approximately half of Caucasian and 
Asian human population are bearing the FGFR4-R388 allele (Bange et al., 2002; Seitzer et 
al., 2010; Stadler et al., 2006; Wang et al., 2004). This G388R SNP in FGFR4 positively 
correlates with prostate cancer risk and aggressive progression of multiple types of cancer. 
We  demonstrate  that  upon  interaction  of  the  FGFR4  variants  and  MT1-MMP,  the  SNP  
functions as a switch of MT1-MMP activity in cancer. The FGFR4-G388 low risk variant and 
MT1-MMP suppress each other’s expression. In contrast, FGFR4-R388 risk variant and 
MT1-MMP enhance pro-migratory FGFR4-FRS2-Src signalling and MT1-MMP proteolytic 
activities, promoting EMT and prostate cancer invasion and invasive growth in mouse 
xenograft models. Due to the opposite effects of FGFR4 variants on MT1-MMP activity, 
unselective targeting of FGFR4 would be expected to result in either beneficial or harmful 
outcome in cancer patients. In our experimental model, FGFR4-G388 gene silencing induced 
upregulation of MT1-MMP and increased tumour spread. We thus anticipate that FGFR4 
SNP genetic background screening and selective targeting to the FGFR4-R388 variant by 
generating specific monoclonal antibodies or small molecules would be useful for 
personalized cancer therapy.    
The EphA2-MT1-MMP axis affects breast carcinoma cell invasion modes between collective 
and single-cell phenotype that can contribute to cancer cell metastasis and escape responses 
to cancer therapy. As summarized in Fig. 10 in III, at cell-cell junctions or upon cell collision 
few ephrin ligands can induce EphA2 clustering and activation. The cleavage of active 
EphA2 by MT1-MMP in protein complexes on the same cell membrane surface triggers the 
receptor internalization by EphA2-dependent Src activity, leading to cell body contraction 
through RhoA activation. This EphA2-MT1-MMP-Src-RhoA signalling regulates repulsive 
cell movement and cell junctional disassembly in both 2D and 3D environment, and 
ultimately single-cell dissemination within 3D collagen matrix and in vivo. Importantly, 
activation and cleavage levels of EphA2 and EphA2-MT1-MMP interaction can regulate 
different types of cancer cell invasion phenotype. For examples, co-expression of MT1-MMP 
and cleavage-prone EphA2-D359I mutant enhances contact-mediated cell repulsion and 
ECM-degradation, resulting in effective rounded single-cell invasion. In contrast, the 
cleavage-resistant EphA2-G391R mutation found in lung cancer induces rapidly and 
collectively invasive cell colony growth, while the kinase activity-deficient proteins 
expressing cells formed cohesive cell colonies with mesenchymal-type elongated cell 
protrusions. Thus, the EphA2-MT1-MMP axis can function in the distinct stage of tumour 
progression, e.g. tumour invasive growth, collective invasion, and single-cell invasion. 
Understanding the regulatory mechanism of EphA2 cleavage and signalling in distinct 
tumour contexts could be helpful in developing strategies for efficient clinical interventions 
for cancer patients in future. Furthermore, generation of monoclonal antibodies or small 
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molecules that selectively bind to the cleavage area of EphA2 would be predicted to inhibit 
EphA2 cleavage and intracellular compartmentalization, which may help to palliate 
metastatic cancer progression by preventing up-regulation of MT1-MMP and cancer cell 
invasion plasticity.  
The broad spectrum synthetic MMP inhibitors have had limited clinical success due to low 
selectivity of inhibitors and because of multiple functions of MMP family members (Devy 
and Dransfield, 2011; Zucker and Cao, 2009). The findings of this thesis study would help to 
alleviate the cancer promoting activities of MT1-MMP by revealing how FGFR4 and EphA2 
co-operate with MT1-MMP during cancer progression. This study could motivate to develop 
strategies of more effective and less toxic anti-invasion and anti-metastasis cancer therapies. 
 ?
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